**CURRICULUM VITAE**

**Name** Giovanni Cazzaniga

**Date and**

**place of birth** 24 September 1965, Vimercate (MI), Italy

**Citizenship** Italian

ORCID ID: 0000-0003-2955-4528

SCOPUS AUTHOR-ID: 7004048814

RESEARCH ID: AFG-4357-2022

**Work addresses**

Tettamanti Center, Pediatrics Medical Genetics

Fond. IRCCS San Gerardo dei Tintori Fondazione IRCCS San Gerardo dei Tintori

 Centro Maria Letizia Verga, Via Cadore snc Via Pergolesi 33

 20900 Monza (Mi), Italy 20900 Monza (Mi), Italy

 Phone:+ 39 039 2332288 / 3661 Phone:+ 39 039 2333461 / 4541

 giovanni.cazzaniga@unimib.it giovanni.cazzaniga@irccs-sangerardo.it

 **EDUCATION**

2021 Associate Professor, Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.

2018 Assistant Professor (Ricercatore a Tempo Determinato di tipo B, RTDB), Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.

2014 Qualification (National Scientific Habilitation, ASN) for Associate Professorship to the following sections: 05/F1 Applied Biology BIO/13 and 06/A1 Medical Genetics MED/03, 06/A2 General and Clinical Pathology (deadline 07/01/2023).

2004 Specialist in Medical Genetics. Faculty of Medicine, University of Milan, Italy. *70/70 cum laude.*

1992 Specialist in Pharmaceutical Research at the “M.Negri” Pharmacology Research Institute of Milan, Italy.

1990 Biological Science degree at the University of Milan, Italy. *110/110 cum laude.*

**PROFESSIONAL POSITION**

05/2023 - now Acting Director (ff), Medical Genetics, Foundation IRCCS San Gerardo dei Tintori, Monza, Italy

03/2023 - now Deputy Director, Ph.D. Program in Translational and Molecular Medicine (Dimet), University of Milan Bicocca.

12/2021 - now Associate Professor, Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.

2006 - now Head, “Molecular genetics of leukemia” Unit, Centro Ricerca Tettamanti, Pediatric Clinic, University of Milan-Bicocca, Monza, Italy.

2018-2021 Assistant Professor (Ricercatore a Tempo Determinato di tipo B, RTDB), Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.

2009 - 04/2023 Director, Laboratory of Hemato-Oncology Diagnostics “M. Tettamanti”, Fondazione MBBM, Monza.

1995/1997 Research fellow at the “M.Tettamanti” Research Center, Pediatric Clinic, University of Milan-Bicocca, Ospedale San Gerardo, Monza, Italy.

1990/1994 Research fellow at the Laboratory of Enzymology - Molecular Biology Unit - "M.Negri" Pharmacology Research Institute, Milan, Italy.

**MAJOR RESEARCH INTERESTS**

* Genetic predisposition to leukemia
* Personalized Medicine in Pediatric Hemato-Oncology
* Prenatal origin of leukemia
* Molecular characterization of childhood ALL and AML.

- Minimal residual disease monitoring in childhood ALL, by analysis of T-cell Receptor and Immunoglobulin genes’ rearrangements and fusion gene transcripts.

- Functional analysis of genetic aberrations in leukemic patients (PAX5 lesions, Ph-like ALL, Down Syndrome ALL, MLL-rearrangements).

**ORGANIZATIONAL / EDUCATIONAL / MANAGERIAL SKILLS**

* Since 2023: Head of the Medical Genetics Unit at the Fondazione IRCCS San Gerardo dei Tintori, Monza (IT), coordinating a team of 2 clinical geneticists, 4 cytogeneticists, 3 molecular biologists, and 6 technicians focused on prenatal and postnatal analyses on genetic disorders, hemato-oncological cytogenetics, clinical genetics focused on cancer predisposition.
* Since 2022: Chair of the Committee on Genetic Variations of the International-BFM Study Group (a Working Group of the European Society for Paediatric Oncology- SIOP Europe, which networks national study groups from more than 30 Countries worldwide, to address research on pediatric leukemia and lymphoma)
* Since 2006: Group Leader of the ‘Molecular Genetics of Leukemia’ Unit at the Tettamanti Research Center, coordinating a team of 3 PostDocs, 2 Physician Scientists, 6 PhD students and 2 rotating ungraduated students.
* 2022: Contributor to 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours (4th Chapter: B-cell lymphoid proliferations and lymphomas - sessions on BCR::ABL1 fusion, ETV6::RUNX1 fusion, ETV6::RUNX1-like features, TCF3::PBX1 fusion, TCF3::HLF fusion). Leukemia. 2022 Jun 22. doi: 10.1038/s41375-022-01613-1.
* 2009-2022: Head of the Laboratory Tettamanti for Hemato-Oncological Diagnostics, coordinating 15 biologists and technicians working on cytomorphology and immunophenotyping, cytogenetics/molecular cytogenetics and molecular biology, for the diagnosis and monitoring of childhood and adult leukemia. The Laboratory if National reference for childhood ALL, and one of the main regional references for CML/MPD.
* Founder and Board Member of the European Group for Minimal Residual Disease (EuroMRD, www.euromrd.org) analysis; Steering Committee member of the Euroclonality-NGS group, member of the Biology & Diagnosis Committee of the International-BFM Study Group (I-BFM-SG); board member of the Working Group on Biology of the Italian Association for Pediatric Hemato-Oncology (AIEOP); Management Committee member of the COST Action ‘Legend’ and vice-chair of WG3 on ‘Familial Leukemia’; Committee of the International PhD in Molecular and Translational Medicine (DIMET-Università Milano Bicocca, Monza).
* Large experience in training and supervising students. Overall, 6 PhD students for the International PhD in Molecular and Translational Medicine (DIMET-Università Milano Bicocca, Monza); 3 PhD students for the International PhD in Molecular Medicine (Università Vita-Salute San Raffaele, Milano);3 students for their post-Degree Specialization in Medicine (Università Milano Bicocca, Monza); 13 students for their degree in Medicine (Università Milano Bicocca, Monza); 12 students for their degree in Biotechnology or Biology (Università Milano Bicocca, Monza and Università degli Studi, Milano); 4 students for their degree as Laboratory Technician (Università Milano Bicocca, Monza).
* Since 2011: yearly Teacher at the Master on Pediatric Hematology, Sapienza University, Rome, IT
* Since 2019: teaching Genetics in courses for Biotechnologists, Technicians and Medical Doctors at University of Milan Bicocca.

**HONOURS AND AWARDS (personal and of the group)**

* 2015 Cazzaniga V/Cazzaniga G. Best Thesis: PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5. 29th National Conference of Cytometry (GIC), Salerno, Italy. Lettere GIC 2011;20:27-30
* 2014 Bardini M/Cazzaniga G. ‘Mundipharma Hematology Award’. National Contest, SIES 2014: Scientific paper: Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia 2015.
* 2014 Palmi C/Cazzaniga G. ‘Under 40- Young in Hematology’, National Contest, SIES 2014: Research Project: ‘CRLF2 Over-expression is a Poor Prognostic Marker in Children With High Risk T-cell ALL’.
* 2006 Palmi C/Cazzaniga G. Best Poster at the 5th Bi-annual Symposium on Childhood Leukemia; ‘Expression of the TEL-AML1 leukemia-associated fusion protein inhibits TGF-beta1 signaling’.
* 2006 Palmi C/Cazzaniga G. Poster “Scholar in Training awardee” at the AACR Special Conference in cancer Research, California (USA).
* 1998 Cazzaniga G. Best abstract at the AIEOP Congress (Pavia). ‘Prenatal origin of leukemia’.
* Several ASH, EHA, SIES travel awards to the personnel of the group through the years.
* Several peer reviewed fellows and University positions to the personnel of the group through the years.
* Advisory Board of the project “Responsible Initiative on Neonatal Genome Sequencing” (RINGS), cofunded by Lombardy Region and Telethon Foundation, to assess the feasibility on Neonatal WGS.

**PEER REVIEWED GRANTS**

As ‘PI’:

Ongoing:

* Italian Association for Cancer Research (AIRC) – IG 2023 ID 29175 (2024-2028): Before leukemia in children: PRE-disposition, PRE-leukemia for PRE-vention (PRE3vent)’ (Euro 1.026.000).
* PRIN: Progetti di Ricerca di Interesse nazionale – Bando 2022, Prot. 2022WMAT29: ‘Precision drug targeting of high risk relapsing childhood acute lymphoblastic leukemia’ Role of Coordinator (Euro 122.702 for the Unit; total Euro 318.950). Granted, to be started.

Completed:

* Italian Association for Cancer Research (AIRC) – 2019-2023 - Childhood Acute Lymphoblastic Leukemia: a path back, from genetic predisposition through pre-leukemia (Euro 687.000).
* TRANSCAN-2 JTC 2017\_Quant-ALL-0622: ‘Automated, absolute quantification of MRD in ALL patients by droplet microfluidics, single DNA copy barcoding and IG/TR amplicon NGS’. PI Unit: G.Cazzaniga (Euro 250.000).
* H2020-MSCA-ITN-2018- Proposal number: 813091: ARCH: Age-Related Changes in Hematopoiesis. PI: Antonella Ronchi (Unimib, Milano, IT); PI Unit: G.Cazzaniga (Euro 252.500)
* Italian Association for Cancer Research (AIRC) – 2016-2018 - A comprehensive sequencing platform for precision medicine in childhood acute lymphoblastic leukemia
* Italian Association for Cancer Research (AIRC) – 2013-2015 -Next Generation Sequencing to improve diagnostics and molecular dissection of childhood leukemia
* Fondazione Cariplo - 2011-2013 - Identification and functional characterization of new risk factors in childhood acute lymphoblastic leukemia.
* Italian Association for Cancer Research (AIRC) – 2010-2012 - High throughput sequencing for dissecting the complexity of childhood ALL.
* Italian Association for Cancer Research (AIRC) – 2007-2009 - Identification of new genomic lesions in childhood ALL with “normal karyotype” by a comprehensive approach.

As ‘Head of Unit’:

* Fight Kids Cancer - Project Number: 22-FKC-21. Project Title: Finding a cure for MLL-rearranged infant acute lymphoblastic leukaemia (Cure2MLL). 2022-23. PI Unit: G.Cazzaniga (Euro 60.000).
* COST Action OC-2016-2-21584 (Call OC-2016-2). PI: Esme Wanders (Utrecht, NL) Leukemia GENe Discovery by data sharing, mining and collaboration (LEGEND). Italian Member: G.Cazzaniga

As ‘Collaborator’:

* Transcan - European Union, FP7 - PI Unit:Andrea Biondi: Validation of the impact of genetic aberrations and host genetic variation in childhood acute lymphoblastic leukemia for integration into clinical practice (Euro 261.884)
* Marie Curie Initial Training Networks (ITN) - Call: FP7-PEOPLE-2011-ITNEuropean Union, FP7 – PI: Antonella Ronchi (Unimib, IT); PI Unit: Andrea Biondi: Hem\_Id - HEMatopoietic cell Identity, genetic and epigenetic regulation in normal and malignant hematopoiesis.
* FP7-HEALTH-F2-2011 Contract no. 261474 - European Union, FP7 - PI Andrea Biondi: ENCCA - European Network for Cancer Research in Children and Adolescents.
* Italian Association for Cancer Research, Fondazione Cariplo, Italian Ministry of University and Research - PI Andrea Biondi: several peer reviewed grants in the last 15 years.

**SOCIETIES**

* Member of the Italian Society of Human Genetics (SIGU)
* Member of the Italian Association of Familial and Hereditary Tumors (AIFET)
* Member of the American Society of Hematology (ASH)
* Member of the European Society of Hematology (EHA)
* Member of the Italian Association of Pediatric Hemato-Oncology (AIEOP)
* Member of the Italian Society of Experimental Hematology (SIES)
* Board Member of the European Study Group for Minimal Residual Disease in Acute Lymphoblastic Leukemia (ESG-MRD ALL)
* Member of the Steering Committee of the Euroclonality-NGS Group.

**COLLABORATIVE PROGRAMS**

2018- now JakNet - Italian network on Ph negative Myeloproliferative Disorders.

2018- now LabNet AML- Italian network on Acute Myeloid Leukemia.

2016-now Campus ALL – Italian network on diagnosis, prognosis and treatment of ALL.

2015-now I-BFM Genetic Variation Task Force. Network on genetic predisposition to leukemia.

2013-now LabNet CML - Italian network on Cronic Myeloid Leukemia

2013-now EuroClonality-NGS Consortium on Next-Generation Sequencing for IG/TR immunogenetic analysis.

2008-now European Study Group on MRD detection in ALL (ESG-MRD-ALL). Standardization and Quality Control of RQ-PCR for BCR/ABL1 and ABL1 mutations.

2002-now European Study Group on MRD detection in ALL (ESG-MRD-ALL). Standardization and Quality Control of Clonality analysis and RQ-PCR for IG/TR.

2000-now MRD-Task Force: Report, Quality Control and Research Projects within the running childhood ALL therapeutic protocol in Italy, Germany, Austria (AIEOP-BFM ALL2000).

1999-now International-BFM Study Group. Biology and Diagnosis Committee.

2016-2021 COST Action OC-2016-2-21584 (Call OC-2016-2). PI: Esme Wanders (Utrecht, NL) Leukemia GENe Discovery by data sharing, mining and collaboration (LEGEND). Italian Member.

1999-2002 Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program.

1995-1998 BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.

* “Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease”.
* “Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets”.

**EDITORIAL ACTIVITIES**

Journal Board

* Associate Editor of the session on Pediatric Hematology and Hematological Malignancies, within Frontiers in Pediatrics.

Referee

* Reviewer of Nature Genetics, New England Journal of Medicine, Blood, Leukemia, Haematologica-The Hematology Journal, Leukemia Research, Leukemia and Lymphoma, Advances in Hematol, Ped Hematol Oncol, Ped Reports, Ped Blood and Cancer, and others.
* Reviewer of International Grant programs, member of the Scientific Committee of the Italian Association for Cancer Research (AIRC) for evaluation of Investigator Grants.
* Abstracts Reviewer for the American Society of Hematology, European Hematology Association and ESLHO meetings.

**PUBLICATIONS / INDEXES**

* Number of total publications in peer-review journals: *274 (including 11 reviews and 3 book chapters)*
* H-Index: 73 (Google Scholar, 07/03/2024)
* Total number of citations: 25185 (Google Scholar, 07/03/2024)
* The ASN 2023-2025 simulation gave positive results for the roles of ‘Full Professor and Committee member’.

I herewith authorize to process my personal data in accordance to Italian D.Lgs. 2018/101 and GDPR (Regulation EU 2016/679).

Monza, 07/03/2024

 Giovanni Cazzaniga

**PUBLICATIONS**

1. Terao M, **Cazzaniga G**, Ghezzi P, Bianchi M, Falciani F, Perani P, Garattini E. Molecular cloning of a cDNA coding for mouse liver xanthine dehydrogenase. Regulation of its transcript by interferons in vivo. *Biochem J* 1992 May 1;283 (Pt 3):863-70
2. Falciani F, Ghezzi P, Terao M, **Cazzaniga G**, Garattini E. Interferons induce xanthine dehydrogenase gene expression in L929 cells.  *Biochem J* 1992 Aug 1;285 ( Pt 3):1001-8
3. Falciani F, Terao M, Goldwurm S, Ronchi A, Gatti A, Minoia C, Li Calzi M, Salmona M, **Cazzaniga G**, Garattini E. Molybdenum(VI) salts convert the xanthine oxidoreductase apoprotein into the active enzyme in mouse L929 fibroblastic cells. *Biochem J* 1994 Feb 15;298 (Pt 1):69-77
4. **Cazzaniga G**, Terao M, Lo Schiavo P, Galbiati F, Segalla F, Seldin MF, Garattini E. Chromosomal mapping, isolation, and characterization of the mouse xanthine dehydrogenase gene. *Genomics* 1994 Sep 15;23(2):390-402
5. Li Calzi M, Raviolo C, Ghibaudi E, de Gioia L, Salmona M, **Cazzaniga G**, Kurosaki M, Terao M, Garattini E. Purification, cDNA cloning, and tissue distribution of bovine liver aldehyde oxidase.  *J Biol Chem* 1995 Dec 29;270(52):31037-45

-------------------------------------------------------------------------------------------------------------------

1. Bertoni F, **Cazzaniga G**, Bosshard G, Roggero E, Barbazza R, De Boni M, Capella C, Pedrinis E, Cavalli F, Biondi A, Zucca E. Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. *Br J Haematol* 1997 Jun;97(4):830-6
2. Caslini C, Spinelli O, **Cazzaniga G**, Golay J, De Gioia L, Pedretti A, Breviario F, Amaru R, Barbui T, Biondi A, Introna M, Rambaldi A. Identification of two novel isoforms of the ZNF162 gene: a growing family of signal transduction and activator of RNA proteins. *Genomics* 1997 Jun 1;42(2):268-77
3. Borkhardt A,\***Cazzaniga G**,\* Viehmann S, Valsecchi MG, Ludwig WD, Burci L, Mangioni S, Schrappe M, Riehm H, Lampert F, Basso G, Masera G, Harbott J, Biondi A. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. *Blood* 1997 Jul 15;90(2):571-7 \*(equal contributors)
4. Tosi S, Mosna G, **Cazzaniga G**, Giudici G, Kearney L, Biondi A, Privitera E. Unbalanced t(3;12) in a case of juvenile myelomonocytic leukemia (JMML) results in partial trisomy of 3q as defined by FISH. *Leukemia* 1997 Sep;11(9):1465-8
5. Biondi A, **Cazzaniga G.** Gli errori della trascrizione nella patologia molecolare della leucemia. Prospettive in Pediatria, 1997, 27:349-356. (*Italian language*)

-------------------------------------------------------------------------------------------------------------------

1. Zucca E, Bertoni F, Roggero E, **Cazzaniga G**, Bosshard G, Biondi A, Cavalli F. Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach.  *Leukemia* 1998 Feb;12(2):247-9
2. Zucca E, Bertoni F, Roggero E, Bosshard G, **Cazzaniga G**, Pedrinis E, Biondi A, Cavalli F. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. *N Engl J Med* 1998 Mar 19;338(12):804-10
3. Tosi S, Giudici G, Mosna G, Harbott J, Specchia G, Grosveld G, Privitera E, Kearney L, Biondi A, **Cazzaniga G.**Identification of new partner chromosomes involved in fusions with the ETV6 (TEL) gene in hematologic malignancies. *Genes Chromosomes Cancer* 1998 Mar;21(3):223-9
4. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, **Cazzaniga G**, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.  *Lancet* 1998 Nov 28;352(9142):1731-8

-------------------------------------------------------------------------------------------------------------------

1. Lo Nigro L, **Cazzaniga G**, Di Cataldo A, Pannunzio A, D'Aniello E, Masera G, Schiliro G, Biondi A. Clonal stability in children with acute lymphoblastic leukemia (ALL) who relapsed five or more years after diagnosis. *Leukemia* 1999 Feb;13(2):190-5
2. Chase A, Reiter A, Burci L, **Cazzaniga G**, Biondi A, Pickard J, Roberts IA, Goldman JM, Cross NC. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). *Blood* 1999 Feb 1;93(3):1025-31
3. Arosio C, Fossati L, Vigano M, Trombini P, **Cazzaniga G**, Piperno A. Hereditary hyperferritinemia cataract syndrome: a de novo mutation in the iron responsive element of the L-ferritin gene.*Haematologica* 1999 Jun;84(6):560-1
4. Wiemels J,\***Cazzaniga G**,\* Daniotti M., Eden T., Masera G., Biondi A. and Greaves M. Pre-natal origin of acute lymphoblastic leukemia in children. *The Lancet*, 1999, 354: 1499-503. \*(equal contributors)
5. **Cazzaniga G.**, S. Tosi, A. Aloisi, G. Giudici, M. Daniotti, P. Pioltelli, L Kearney and A. Biondi. The tyrosine kinase *Abl*-related gene *ARG* is fused to *ETV6* in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. *Blood. 1999;94:4370-3.*
6. Bertoni F., Zucca E., Genini D., **Cazzaniga G.**, Roggero E., Ghielmini M., Cavalli F., and Biondi A. Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle-cell lymphoma..*Leuk Lymphoma. 1999;36:147-50.*
7. **Cazzaniga G**, Gottardi E, Volpe G, Toiron Y, Waronko A, Biondi A, Saglio G, Gabert JA. t(12;21)(p13;q22) with the TEL-AML1 fusion gene. in van Dongen JJ et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-28.

-------------------------------------------------------------------------------------------------------------------

1. Bertoni F, Sanna P, Tinguely M, Roggero E, Conconi A, Gisi M, **Cazzaniga G**, Biondi A, Pedrinis E, Cavalli F, Zucca E. Association of gastric and Waldeyer's ring lymphoma: a molecular study. *Hematol Oncol*. 2000 Mar;18(1):15-9.
2. De Zen L, Orfao A, **Cazzaniga G**, Masiero L, Cocito MG, Spinelli M, Rivolta A, Biondi A, Zanesco L, Basso G. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. *Leukemia*. 2000 Jul;14(7):1225-31.
3. Wiemels JL, Alexander FE, **Cazzaniga G**, Biondi A, Mayer SP, Greaves M. Microclustering of TEL-AML1 translocation breakpoints in childhood acute lymphoblastic leukemia. *Genes Chromosomes Cancer*. 2000 Nov;29(3):219-28.
4. Tosi S, Harbott J, Teigler-Schlegel A, Haas OA, Pirc-Danoewinata H, Harrison CJ, Biondi A, **Cazzaniga G**, Kempski H, Scherer SW, Kearney L. t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. *Genes Chromosomes Cancer*. 2000 Dec;29(4):325-32.

-------------------------------------------------------------------------------------------------------------------

1. **Cazzaniga G**, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E, Kearney L, Biondi A. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. *Cancer Res*. 2001 Jun 15;61(12):4666-70.
2. Eckert C, Biondi A, Seeger K, **Cazzaniga G**, Hartmann R, Beyermann B, Pogodda M, Proba J, Henze G. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. *Lancet*. 2001 Oct 13;358(9289):1239-41.
3. Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A, **Cazzaniga G**, Lendahl U, Fehling HJ, Hayday AC, Frati L, von Boehmer H, Gulino A, Screpanti I. Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. *Proc Natl Acad Sci U S A*. 2002 Mar 19;99(6):3788-93.
4. Bertoni F, Conconi A, Capella C, Motta T, Giardini R, Ponzoni M, Pedrinis E, Novero D, Rinaldi P, **Cazzaniga G**, Biondi A, Wotherspoon A, Hancock BW, Smith P, Souhami R, Cotter FE, Cavalli F, Zucca E. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. *Blood*. 2002 Apr 1;99(7):2541-4.
5. **Cazzaniga G**, Rossi V, Biondi A. Monitoring minimal residual disease using chromosomal translocations in childhood ALL. *Best Pract Res Clin Haematol*. 2002 Mar;15(1):21-35. (review)
6. Carlotti E, Pettenella F, Amaru R, Slater S, Lister TA, Barbui T, Basso G, **Cazzaniga G**, Rambaldi A, Biondi A. Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia. *Br J Haematol*. 2002 Sep;118(4):1011-8.
7. **Cazzaniga G**, Lanciotti M, Rossi V, Di Martino D, Arico M, Valsecchi MG, Basso G, Masera G, Micalizzi C, Biondi A. Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. Br J Haematol. 2002 Nov;119(2):445-53.
8. **Cazzaniga G**, d'Aniello E, Corral L, Biondi A. Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL. Best Pract Res Clin Haematol. 2002;15:623-38. (review)

-------------------------------------------------------------------------------------------------------------------

1. Corti P, Bonanomi S, Vallinoto C, Balduzzi A, Uderzo C, **Cazzaniga G**, Gaipa G, Dassi M, Perseghin P, Rovelli A. Rituximab for immune hemolytic anemia following T- and B-Cell-depleted hematopoietic stem cell transplantation. Acta Haematol. 2003;109:43-5.
2. Arrigoni P, Beretta C, Silvestri D, Rossi V, Rizzari C, Valsecchi MG, **Cazzaniga G**, Biondi A. FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. Br J Haematol. 2003;120:89-92.
3. van der Velden VH, Hochhaus A, **Cazzaniga G**, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003 Jun;17(6):1013-34. (review)
4. Germano G, del Giudice L, Palatron S, Giarin E, **Cazzaniga G**, Biondi A, Basso G. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.Leukemia. 2003 Aug;17(8):1573-82.
5. Gunby RH, **Cazzaniga G**, Tassi E, Le Coutre P, Pogliani E, Specchia G, Biondi A, Gambacorti-Passerini C. Sensitivity to imatinib but low frequency of the TEL/PDGFRb fusion protein in chronic myelomonocytic leukemia. Haematologica. 2003;88:408-15.
6. Tosi S, Hughes J, Scherer SW, Nakabayashi K, Harbott J, Haas OA, **Cazzaniga G**, Biondi A, Kempski H, Kearney L. Heterogeneity of the 7q36 breakpoints in the t(7;12) involving ETV6 in infant leukemia. Genes Chromosomes Cancer. 2003;38:191-200.
7. Scrideli CA, **Cazzaniga G**, Fazio G, Pirola L, Callegaro A, Bassan R, Rambaldi A, Nigro LL, Basso G, Masera G, Biondi A. Gene expression profile unravels significant differences between childhood and adult Ph+ acute lymphoblastic leukemia. Leukemia. 2003;17:2234-2237.
8. **Cazzaniga G**, Gaipa G, Rossi V and Biondi A. Minimal residual disease as a surrogate marker for risk assignment to ALL patients. Rev Clin Exp Hematol. 2003;7:292-323 (review)
9. Eckert C, Scrideli CA, Taube T, Songia S, Wellmann S, Manenti M, Seeger K, Biondi A, **Cazzaniga G**. Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes. Leukemia. 2003;17:2517-24.
10. Gabert J, Beillard E, Van Der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, **Cazzaniga G**, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, Van Dongen JJ. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 2003;17:2318-57.

-------------------------------------------------------------------------------------------------------------------

1. Hubner S\*, **Cazzaniga G**\*, Flohr T, Van Der Velden VH, Konrad M, Potschger U, Basso G, Schrappe M, Van Dongen JJ, Bartram CR, Biondi A, Panzer-Grumayer ER. High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias. Leukemia. 2004 ;18:84-91. \*(equal contributors)
2. Tartaglia M, Martinelli S, **Cazzaniga G**, Cordeddu V, Spinelli M, Palmi C, Carta C, Pession A, Aricò M, Masera G, Basso G, Sorcini M, Gelb BD, and Biondi A. Genetic evidence for lineage- and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood. 2004;104:307-13.
3. Maia AT, Tussiwand R, **Cazzaniga G**, Rebulla P, Colman S, Biondi A and Greaves MF. Identification Of Pre-Leukemic Precursors Of Hyperdiploid Acute Lymphoblastic Leukemia In Cord Blood. Genes Chromosomes Cancer. 2004; 40:38-43.
4. Beretta C, Gaipa G, Rossi V, Bernasconi S, Spinelli O, Dell’Oro MG, Rizzari C, Rambaldi A, Biondi A and **Cazzaniga G**. Development of a quantitative-PCR method for specific FLT3/ITD monitoring in Acute Myeloid Leukemia. Leukemia. 2004;18:1441-4
5. Beghini A, Ripamonti CB, Cairoli R, **Cazzaniga G**, Colapietro P, Elice F, Nadali G, Grillo G, Haas OA, Biondi A, Morra E, Larizza L. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica. 2004;89:920-5.

-------------------------------------------------------------------------------------------------------------------

1. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, **Cazzaniga G**, Bugarin C, Veltroni M, Michelotto B, Ratei R, Coliva T, Valsecchi MG, Biondi A, Dworzak M. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2005;19:49-56.
2. Cittera E, Onofri C, D'Apolito M, Cartron G, **Cazzaniga G**, Zelante L, Paolucci P, Biondi A, Introna M, Golay J. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunol Immunother. 2005;54:273-86.
3. **Cazzaniga G**, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica. 2005;90:382-90. (review)
4. Tartaglia M, Martinelli S, Iavarone I, **Cazzaniga G**, Spinelli M, Giarin E, Petrangeli V, Carta C, Masetti R, Arico M, Locatelli F, Basso G, Sorcini M, Pession A, Biondi A. Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br J Haematol. 2005;129:333-9.
5. **Cazzaniga G**, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, Locatelli F, Martelli MF, Basso G, Pession A, Biondi A, Falini B. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005 Aug 15;106(4):1419-22.
6. Panzer-Grümayer ER, **Cazzaniga G**, van der Velden VHJ, del Giudice L, Peham M, Mann G, Eckert C, Schrauder A, Germano G, Harbott J, Basso G, Biondi A, van Dongen JJM,Gadner H and Haas OA. Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection. Clin Cancer Res. 2005 Nov 1;11(21):7720-7.

-------------------------------------------------------------------------------------------------------------------

1. Palmi C, Fazio G, Cassetti A, Aloisi A, Villa A, Biondi A, and **Cazzaniga G**. TEL/ARG induces cytoskeletal abnormalities in 293T cells. Cancer Lett. 2006 Sep 8;241(1):79-86.
2. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, **Cazzaniga G**, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli MF, Gu W, Mecucci C, Nicoletti I. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006 Jun 1;107(11):4514-23.
3. Golay J, Cortiana C, Manganini M, **Cazzaniga** G, Salvi A, Spinelli O, Bassan R, Barbui T, Biondi A, Rambaldi A, Introna M. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica. 2006 Mar;91(3):322-30.
4. Gorello P,\***Cazzaniga** G,\* Alberti F, Dell'Oro MG, Gottardi E, Specchia G, Roti G, Rosati R, Martelli MF, Diverio D, Lo Coco F, Biondi A, Saglio G, Mecucci C, Falini B. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006 Jun;20(6):1103-8. \*(equal contributors)
5. Bungaro S, Raghavan M, Dell'Oro MG, Paolucci P, Young BD, Biondi A, **Cazzaniga** G. Assessment of submicroscopic genetic lesions by single nucleotide polymorphism arrays in a child with acute myeloid leukemia and FLT3-internal tandem duplication. Haematologica. 2006 Jul;91(7):998-1000.
6. Staal FJ, Cario G, **Cazzaniga** G, Haferlach T, Heuser M, Hofmann WK, Mills K, Schrappe M, Stanulla M, Wingen LU, van Dongen JJ, Schlegelberger B. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia. 2006;20:1385-92.
7. **Cazzaniga G**, Gaipa G, Rossi V, Biondi A. Monitoring of minimal residual disease in leukemia, advantages and pitfalls. Annals of Medicine. 2006;38:512-21.(**review**)

-------------------------------------------------------------------------------------------------------------------

1. van der Velden VHJ, **Cazzaniga G**, Schrauder A, Hancock J, Bader P, Panzer-Grumayer R, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela J-M, Trka J, Eckert C, Foroni L, zur Stadt U, Beldjord K, Raff T, C. van der Schoot CE, van Dongen JJM On behalf of the European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604-11.
2. Georg Mann\*, Giovanni **Cazzaniga**\*, Vincent HJ van der Velden, Thomas Flohr, Eva Csinady, Maddalena Paganin, Andre Schrauder, Alexander M Dohnal, Martin Schrappe, Andrea Biondi, Helmut Gadner, Jacques JM van Dongen and E Renate Panzer-Grümayer. Acute lymphoblastic leukemia with t(4;11) in children one year and older: The “big sister” of the infant disease? Leukemia. 2007;21:642-6.\*(equal contributors)
3. van der Velden VH, Panzer-Grumayer ER, **Cazzaniga G**, Flohr T, Sutton R, Schrauder A, Basso G, Schrappe M, Wijkhuijs JM, Konrad M, Bartram CR, Masera G, Biondi A, van Dongen JJ. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia. 2007;21:706-13.
4. Saldanha J, Silvy M, Beaufils N, Arlinghaus R, Barbany G, Branford S, Cayuela JM, **Cazzaniga G**, Gonzalez M, Grimwade D, Kairisto V, Miyamura K, Lawler M, Lion T, Macintyre E, Mahon FX, Muller MC, Ostergaard M, Pfeifer H, Saglio G, Sawyers C, Spinelli O, van der Velden VH, Wang JQ, Zoi K, Patel V, Phillips P, Matejtschuk P, Gabert J. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia. 2007;21:1481-7.
5. Accordi B, Pillozzi S, Campo Dell'orto M, **Cazzaniga G**, Arcangeli A, Te Kronnie G, Basso G. Hepatocyte growth factor receptor c-MET is associated with FAS and when activated enhances drug-induced apoptosis in pediatric B-acute lymphoblastic leukemia with TEL-AML1 translocation. J Biol Chem. 2007;282:29384-93.

-------------------------------------------------------------------------------------------------------------------

1. Bungaro S, Irving J, Tussiwand R, Mura R, Minto L, Molteni C, Citterio M, Hall A, Biondi A, **Cazzaniga G**. Genomic analysis of different clonal evolution in a twin pair with t(12;21) positive acute lymphoblastic leukemia sharing the same prenatal clone. Leukemia. 2008;22:208-11
2. Corradi B, Fazio G, Palmi C, Rossi V, Biondi A, **Cazzaniga G**. Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform. Leukemia. 2008;22:294-302.
3. Fazio C, Palmi C, Rolink A, Biondi A and **Cazzaniga G**. PAX5/TEL acts as a transcriptional repressor causing down modulation of CD19, enhances migration to CXCL12 and confers survival advantage in preBI cells. Cancer Res. 2008;68:181-9.
4. Flohr T,\* Schrauder A,\* **Cazzaniga G**,\* Panzer-Grümayer R, van der Velden VHJ, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJM, Biondi A, Bartram CR, on behalf of the International BFM Study Group (I-BFM-SG). Minimal residual disease (MRD)-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia (ALL). Leukemia. 2008;22:771-82. \*(equal contributors)
5. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, Ariola C, Fodale V, Clappier E, Paoloni F, Martinelli S, Fragale A, Sanchez M, Tavolaro S, Messina M, **Cazzaniga G**, Camera A, Pizzolo G, Tornesello A, Vignetti M, Battistini A, Cavé H, Gelb BD, Renauld JC, Biondi A, Constantinescu SN, Foà R, Tartaglia M. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.J Exp Med. 2008;205:751-8.
6. Arico M, Ziino O, Valsecchi MG, **Cazzaniga G**, Baronci C, Messina C, Pession A, Santoro N, Basso G, Conter V; for the Italian Association of Pediatric Hematology and Oncology (AIEOP).Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Cancer. 2008;113:515-521.
7. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, Shochat C, **Cazzaniga G**, Biondi A, Basso G, Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Mann G, Binder V, Borkhardt A, Kempski H, Trka J, Bielorei B, Avigad S, Stark B, Smith O, Dastugue N, Bourquin JP, Tal NB, Green AR, Izraeli S. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372:1484-92

-------------------------------------------------------------------------------------------------------------------

1. **Cazzaniga G**, Lo Nigro L, Cifola I, Milone G, Schnittger S, Haferlach T, Mirabile E, Costantino F, Martelli MP, Mastrodicasa E, Di Raimondo F, Aversa F, Biondi A, Falini B. Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family. Leukemia. 2009;23:199-203.
2. Bungaro S, Dell'Orto MC, Zangrando A, Basso D, Gorletta T, Lo Nigro L, Leszl A, Young BD, Basso G, Bicciato S, Biondi A, Te Kronnie G, **Cazzaniga G**. Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. Genes Chromosomes Cancer. 2009;48:22-38.
3. Van der Velden V,\* Corral L,\* Valsecchi MG,\* Jansen MWJC,\* De Lorenzo P, **Cazzaniga G**, Panzer-Grümayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Lo Nigro L, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJM. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009;23:1073-9 \*(equal contributors)
4. Ford A,\* Palmi C,\* Bueno C, Hong D, Cardus P, Knight D, **Cazzaniga G**, Enver T, Greaves M. The TEL/AML1 leukaemia fusion gene dysregulates the TGFb pathway in early B lineage progenitor cells. J. Clinical Invest. 2009;119:826-36. \*(equal contributors)
5. Willasch A, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H, Steinbach D, Weber G, Hollink IHIM, Zwaan CM, Biondi A, van der Velden VHJ, Reinhardt D, **Cazzaniga G**,\* Bader P\* and Trka J.\* Standardization of WT1 mRNA quantitation for minimal residual disease (MRD) monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia 2009;23:1472-9 \*(equal contributors)
6. Emerenciano M, Bungaro S, **Cazzaniga G**, Fonseca Dorea MD, Coser VM, Quezado Magalhaes I, Biondi A, Pombo-de-Oliveira MS. ETV6-RUNX1 fusion gene and additional genetic changes in infant leukemia: a genome-wide analysis.Cancer Genet and Cytogenet 2009;193:86.
7. Lovisa F, Mussolin L, Corral L, Pillon M, **Cazzaniga** G, Biondi A, and Rosolen A. IgH and IgK gene rearrangements as PCR targets for pediatric Burkitt’s lymphoma and mature B-ALL MRD analysis. Lab Invest. 2009;89:1182-6.

-------------------------------------------------------------------------------------------------------------------

1. Molteni CG, Te Kronnie G, Bicciato S, Villa T, Tartaglia M, Basso G, Biondi A, **Cazzaniga G**. PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy. Leukemia. 2010;24:232-5
2. Bardini M, Spinelli R, Bungaro S, Mangano E, Corral L, Cifola I, Fazio G, Giordan M, Basso G, De Rossi G, Biondi A, Battaglia C, **Cazzaniga G**. DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia. 2010;24:169-76
3. Hertzberg L, Vendramini E, Ganmore I, **Cazzaniga G**, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, Kronnie GT, Bourquin JP, Domany E, Izraeli S. Down syndrome acute lymphoblastic leukemia: a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the iBFM Study Group. Blood. 2010;115:1006-17
4. Bateman CM, Colman SM, Chaplin T, Young BD, Eden TO, Bhakta M, Gratias EJ, van Wering ER, **Cazzaniga G**, Harrison CJ, Hain R, Ancliff P, Ford AM, Kearney L, Greaves M. Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukaemia. Blood. 2010;115:3553-8.
5. Buldini B, Zangrando A, Michielotto B, Veltroni M, Giarin E, Tosato F, **Cazzaniga G**, Biondi A, Basso G. Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2010;85:138-41.
6. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, Arico M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, **Cazzaniga G**, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206-14.
7. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, **Cazzaniga G**, Biondi A, Miranda-Saavedra D, Göttgens B, Saffery R, Craig JM, Marshall GM, Gambacorti-Passerini C, Pimanda JE, Lock RB. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010;116:3013-22.

-------------------------------------------------------------------------------------------------------------------

1. Bardini, M Galbiati, A Lettieri, S Bungaro, TA Gorletta, A Biondi and **G Cazzaniga**. Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients. Leukemia. 2011;25:175-8.
2. M Pigazzi, G Ferrari, R Masetti, B Falini, F Martinolli, G Basso, A Biondi, A Pession and **G Cazzaniga**. Low prevalence of IDH1 gene mutation in childhood AML in Italy. Leukemia. 2011;25:173-4
3. Capelli C, Gotti E, Morigi M, Rota C, Weng L, Dazzi F, Spinelli O, **Cazzaniga G**, Trezzi R, Gianatti A, Rambaldi A, Golay J, Introna M. Minimally manipulated whole human umbilical cord is a very rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy. 2011;13:786-801.
4. Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, Te Kronnie G, Cario G, **Cazzaniga G**, Kulozik AE, Stanulla M, Schrappe M, Biondi A, Basso G, Bercovich D, Muckenthaler MU, Izraeli S. Gain-of-function mutations in interleukin-7 receptor-{alpha} (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 2011;208:901-8.
5. Ballabio E, Regan R, Garimberti E, Harbott J, Bradtke J, Teigler-Schlegel A, Biondi A, **Cazzaniga G**, Giudici G, Wainscoat JS, Boultwood J, Bridger JM, Knight SJL, Tosi S. Genomic imbalances are confined to non-proliferating cells in paediatric patients with acute myeloid leukaemia and a normal karyotype. PLoS One. 2011;6(6):e20607.
6. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grümayer R, Möricke A, Parasole R, Zimmermann M, Dworzak M, Buldini B, Reiter A, Basso G, Klingebiel T, Messina C, Ratei R, **Cazzaniga G**, Köhler R, Locatelli F, Schäfer BW, Aricò M, Welte K, van Dongen JJ, Gadner H, Biondi A, Conter V. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077-2084
7. **Cazzaniga G**, Valsecchi MG, Gaipa G, Conter V, Biondi A. Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia. Br J Haematol. 2011;155:45-52.
8. Paganin M, Pigazzi M, Bresolin S, Masetti R, Fagioli F, Chiaretti S, **CazzanigaG**, Locatelli F, Pession A, Te Kronnie G, Basso G. DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T cell acute lymphoblastic leukemia: an Italian study. Haematologica. 2011;96:1886-7.
9. Rizzari C, **Cazzaniga G**, Coliva T, De Angelis C, Conter V. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease. Expert Rev Anticancer Ther. 2011;11:1391-401.
10. Elia L, Grammatico S, Paoloni F, Vignetti M, Rago A, Cenfra N, Mecarocci S, Mancini M, Luciani M, Di Raimondo F, **Cazzaniga G**, Matarazzo M, Moleti ML, Santoro L, Gaidano G, Foà R, Mandelli F, Cimino G. Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene. Am J Hematol. 2011;86:993-7.
11. **Cazzaniga G**, van Delft FW, Lo Nigro L, Ford AM, Score J, Iacobucci I, Mirabile E, Taj M, Colman SM, Biondi A, Greaves M. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukaemia. Blood. 2011;118:5559-64.
12. Basso K, Mussolin L, Lettieri A, Brahmachary M, Lim WK, Califano A, Basso G, Biondi A, **Cazzaniga G**, Rosolen A. T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Cancer. 2011;50:1063-75.
13. Fazio G, Biondi A and **Cazzaniga G**. The Role of PAX5 in ALL, in ‘Novel Aspects in Acute Lymphoblastic Leukemia’, edited by Stefan Faderl, ISBN 978-953-307-753-6, InTech, November 11, 2011 (**book chapter**)

-------------------------------------------------------------------------------------------------------------------

1. Palmi C, Vendramini E, Silvestri D, Longinotti G, Frison D, Cario G, Shochat C, Stanulla M, Rossi V, Di Meglio AM, Villa T, Giarin E, Fazio G, Leszl A, Schrappe M, Basso G, Biondi A, Izraeli S, Conter V, Valsecchi MG, **Cazzaniga G**,\* Te Kronnie G.\* Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia. 2012 Oct;26(10):2245-53. **\*(co-last authors)**
2. Ellinghaus E, Stanulla M, Richter G, Ellinghaus D, Te Kronnie G, Cario G, **Cazzaniga G**, Horstmann M, Panzer Grümayer R, Cavé H, Trka J, Cinek O, Teigler-Schlegel A, Elsharawy A, Häsler R, Nebel A, Meissner B, Bartram T, Lescai F, Franceschi C, Giordan M, Nürnberg P, Heinzow B, Zimmermann M, Schreiber S, Schrappe M, Franke A. Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia 2012;26,902–909
3. Gaipa G, **Cazzaniga G**,\* Valsecchi MG, Panzer-Grümayer R, Buldini B, Silvestri D, Karawajew L, Maglia O, Ratei R, Benetello A, Sala S, Schumich A, Schrauder A, Villa T, Veltroni M, Ludwig WD, Conter V, Schrappe M, Biondi A, Dworzak M, Basso G. Time point-dependent concordance of flow cytometry and RQ-PCR in minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica. 2012 Oct;97(10):1582-93. **\*(co-first author)**
4. Attarbaschi A, Morak M, Cario G, **Cazzaniga G**, Ensor HM, Te Kronnie T, Bradtke J, Mann G, Vendramini E, Palmi C, Schwab C, Russell LJ, Schrappe M, Conter V, Mitchell CD, Strehl S, Zimmermann M, Pötschger U, Harrison CJ, Stanulla M, Panzer-Grümayer R, Haas OA, Moorman AV; on behalf of the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP)-Berlin-Frankfurt-Münster (BFM) Study Group and National Cancer Research Institute (NCRI)-Children's Cancer and Leukaemia (CCLG) Study Group. Treatment outcome of CRLF2 -rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. Br J Haematol. 2012 Sep;158(6):772-777.
5. Martinelli S, Checquolo S, Consoli F, Stellacci E, Rossi C, Silvano M, Franciosa G, Flex E, Cossu C, De Luca A, Foà R, **Cazzaniga G**, Biondi A, Screpanti I, Tartaglia M. Loss of CBL E3-ligase activity in B-lineage childhood acute lymphoblastic leukaemia. Br J Haematol. 2012 Oct;159(1):115-9.
6. André V, Longoni D, Bresolin S, Cappuzzello C, Dander E, Galbiati M, Bugarin C, Di Meglio A, Nicolis E, Maserati E, Serafini M, Warren AJ, te Kronnie G, **Cazzaniga G**, Sainati L, Cipolli M, Biondi A and D'Amico G. Mesenchymal stem cells from Shwachman–Diamond syndrome patients display normal functions and do not contribute to hematological defects. Blood Cancer Journal (2012) 2, e94; doi:10.1038/bcj.2012.40 Published online 12 October 2012.
7. Lutz C, Woll PS, Hall G, Castor A, Dreau H, **Cazzaniga G**, Zuna J, Jensen C, Clark SA, Biondi A, Mitchell C, Ferry H, Schuh A, Buckle V, Jacobsen SE, Enver T. Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia. Leukemia. 2012 Oct 22. doi: 10.1038/leu.2012.306. [Epub ahead of print]
8. Fazio G, Cazzaniga V, Palmi C, Galbiati M, Giordan M, Te Kronnie G, Rolink A, Biondi A, **Cazzaniga G**. PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5. Leukemia. 2013;27:992-5
9. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, **Cazzaniga G**, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Döhner K, Döhner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR.. An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell. 2012;22(5): November 12, 2012
10. Franca R, Rebora P, Basso G, Biondi A, **Cazzaniga G**, Crovella S, Decorti G, Fagioli F, Giarin E, Locatelli F, Poggi V, Valsecchi MG, Rabusin M. Glutathione S-transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort. Pharmacogenomics. 2012;13:1905-16.

-------------------------------------------------------------------------------------------------------------------

1. Galbiati M, Lettieri A, Micalizzi C, Songia S, Morerio C, Biondi A, Dufour C, **Cazzaniga G**. Natural history of acute lymphoblastic leukemia in neurofibromatosis type 1 monozygotic twins. Leukemia. 2013 Aug;27(8):1778-81
2. Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, Bungaro S, **Cazzaniga G**, Rambaldi A, Introna M, Pesenti E, Alzani R. The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56(+) Acute Monoblastic Leukaemia. PLoS One. 2013;8(3):e58424.
3. Ma Y, Dobbins SE, Sherborne AL, Chubb D, Galbiati M, **Cazzaniga G**, Micalizzi C, Tearle R, Lloyd AL, Hain R, Greaves M, Houlston RS. Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7429-33
4. Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V, Basso G, Biondi A, Te Kronnie G, **Cazzaniga G**. What is the relevance of Ikaros gene deletions as prognostic marker in pediatric Philadelphia negative B-cell precursor acute lymphoblastic leukemia? Haematologica. 2013 Aug;98(8):1226-31
5. Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cavé H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsaur G, Fechina L, van der Velden VH, van Dongen JJ, Delabesse E, Binato R, Silva ML, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi WW, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan MB, Cayuela JM, Herbaux C, **Cazzaniga G**, Kakadiya PM, Bohlander S, Ahlmann M, Choi JR, Gameiro P, Lee DS, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schäfer BW, Kubetzko S, Alonso CN, Zur Stadt U, Sutton R, Venn NC, Izraeli S, Trakhtenbrot L, Madsen HO, Archer P, Hancock J, Cerveira N, Teixeira MR, Lo Nigro L, Möricke A, Stanulla M, Schrappe M, Sedék L, Szczepański T, Zwaan CM, Coenen EA, van den Heuvel-Eibrink MM, Strehl S, Dworzak M, Panzer-Grümayer R, Dingermann T, Klingebiel T, Marschalek R. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013 Nov;27(11):2165-76
6. Lo Nigro L, Mirabile E, Tumino M, Caserta C, **Cazzaniga G**, Rizzari C, Silvestri D, Buldini B, Barisone E, Casale F, Luciani M, Locatelli F, Messina C, Micalizzi C, Pession A, Parasole R, Santoro N, Masera G, Basso G, Aricò M, Valsecchi MG, Biondi A, Conter V. Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-Lineage acute lymphoblastic leukemia. Leukemia. 2013 Dec;27(12):2419-21
7. Brandimarte L, Pierini V, Di Giacomo D, Borga C, Nozza F, Gorello P, Giordan M, **Cazzaniga G**, Te Kronnie G, La Starza R, Mecucci C. New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia. Blood. 2013 Jun 20;121(25):5064-7.
8. Chiaretti S, Vitale A, **Cazzaniga G**, Orlando SM, Silvestri D, Fazi P, Valsecchi MG, Elia L, Testi AM, Mancini F, Conter V, Te Kronnie G, Ferrara F, Di Raimondo F, Tedeschi A, Fioritoni G, Fabbiano F, Meloni G, Specchia G, Pizzolo G, Mandelli F, Guarini A, Basso G, Biondi A, Foa' R. Clinico-biologic features of 5202 acute lymphoblastic leukemia patients enrolled in the Italian AIEOP and GIMEMA Protocols and stratified in age-cohorts. Haematologica. 2013 Nov;98(11):1702-10
9. La Starza R, Lettieri A, Pierini V, Nofrini V, Gorello P, Songia S, Crescenzi B, Te Kronnie G, Giordan M, Leszl A, Valsecchi MG, Aversa F, Basso G, Biondi A, Conter V, **Cazzaniga G**, Mecucci C. Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia. Leuk Res. 2013;37:928-35
10. Dobbins SE, Sherborne AL, Ma YP, Bardini M, Biondi A, **Cazzaniga G**, Lloyd A, Chubb D, Greaves MF, Houlston RS. The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia.Genes Chromosomes Cancer. 2013;52:954-60
11. Potter NE, Ermini L, Papaemmanuil E, **Cazzaniga G**, Vijayaraghavan G, Titley I, Ford A, Campbell P, Kearney L, Greaves M. Single cell mutational profiling and clonal phylogeny in cancer. Genome Res. 2013 Dec;23(12):2115-25
12. Piazza R, Magistroni V, Pirola A, Redaelli S, Spinelli R, Redaelli S, Galbiati M, Valletta S, Giudici G, **Cazzaniga G**, Gambacorti-Passerini C. CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data. PLoS One. 2013 Oct 4;8(10):e74825.
13. Biondi A, **Cazzaniga G**. Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses. Hematology Am Soc Hematol Educ Program. 2013;2013:612-9.
14. Palmi C, Lana T, Silvestri D, Savino A, Kronnie GT, Conter V, Basso G, Biondi A, Valsecchi MG, **Cazzaniga G**. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". Haematologica. 2013;98:e164-5.

-------------------------------------------------------------------------------------------------------------------

1. Pagni F, Fazio G, Zannella S, Spinelli M, De Angelis C, Cusi C, Crosti F, Corral L, Bugarin C, Biondi A, **Cazzaniga G**,\* Isimbaldi G, Cattoretti G. The role of PAX5 and C/EBP α/β in atypical non-Langerhans cell histiocytic tumor post acute lymphoblastic leukemia. Leukemia. 2014;28:1377-9 **\*(corresponding author)**
2. Balduzzi A, Di Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A, Conter V, Biondi A, **Cazzaniga G**,\* Valsecchi MG. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br J Haematol. 2014;164:396-408. **(\*co-last author)**
3. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, van Delft FW, Nik-Zainal S, Jones DR, Ramakrishna M, Titley I, Stebbings L, Leroy C, Menzies A, Gamble J, Robinson B, Mudie L, Raine K, O'Meara S, Teague JW, Butler AP, **Cazzaniga G**, Biondi A, Zuna J, Kempski H, Muschen M, Ford AM, Stratton MR, Greaves M, Campbell PJ. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014;46:116-25.
4. van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, Cavé H, Trka J, Saha V, Schrappe M, Pieters R, Biondi A, Valsecchi MG, Stanulla M, den Boer ML, **Cazzaniga G**. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood. 2014;123:1691-8.
5. Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA, Devidas M, Strehl S, Nebral K, Harbott J, Teigler-Schlegel A, Zimmerman M, Dastuge N, Baruchel A, Soulier J, Auclerc MF, Attarbaschi A, Mann G, Stark B, **Cazzaniga G**, Chilton L, Vandenberghe P, Forestier E, Haltrich I, Raimondi SC, Parihar M, Bourquin JP, Tchinda J, Haferlach C, Vora A, Hunger SP, Heerema NA, Haas OA. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia. 2014;28:1015-21.
6. Meissner B, Bartram T, Eckert C, Trka J, Panzer-Grümayer R, Hermanova I, Ellinghaus E, Franke A, Möricke A, Schrauder A, Teigler-Schlegel A, Dörge P, von Stackelberg A, Basso G, Bartram CR, Kirschner-Schwabe R, Bornhäuser B, Bourquin JP, **Cazzaniga G**, Hauer J, Attarbaschi A, Izraeli S, Zaliova M, Cario G, Zimmermann M, Avigad S, Sokalska-Duhme M, Metzler M, Schrappe M, Koehler R, Kronnie GT, Stanulla M. Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia. Hum Mol Genet. 2014;23:590-601
7. Shochat C, Tal N, Gryshkova V, Birger Y, Bandapalli OR, **Cazzaniga G**, Gershman N, Kulozik AE, Biondi A, Mansour MR, Twizere JC, Muckenthaler MU, Ben-Tal N, Constantinescu SN, Bercovich D, Izraeli S. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood. 2014 May 1. [Epub ahead of print]
8. Bardini M, Woll PS, Corral L, Luc S, Wittmann L, Ma Z, Lo Nigro L, Basso G, Biondi A, **Cazzaniga G**,\* Jacobsen SE\*. Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia. 2014 May 6. doi: 10.1038/leu.2014.154. [Epub ahead of print] **\*(co-corresponding authors)**
9. Milani G, Rebora P, Accordi B, Galla L, Bresolin S, **Cazzaniga G**, Buldini B, Mura R, Ladogana S, Giraldi E, Conter V, Te Kronnie G, Valsecchi MG, Basso G. Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. Oncotarget. 2014;5:5234-45.
10. Palmi C, Fazio G, Savino AM, Procter J, Howell L, Cazzaniga V, Vieri M, Longinotti G, Brunati I, Andrè V, Della Mina P, Villa A, Greaves M, Biondi A, D'Amico G, Ford A, **Cazzaniga G**. Cytoskeletal Regulatory Gene Expression and Migratory Properties of B-cell Progenitors Are Affected by the ETV6-RUNX1 Rearrangement. Mol Cancer Res. 2014;12:1796-806.
11. La Starza R, Borga C, Barba G, Pierini V, Schwab C, Matteucci C, Lema Fernandez AG, Leszl A, **Cazzaniga G**, Chiaretti S, Basso G, Harrison CJ, Te Kronnie G, Mecucci C. Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. Blood. 2014;124:3577-82.
12. Paganin M, Fabbri G, Conter V, Barisone E, Polato K, **Cazzaniga G**, Giraldi E, Fagioli F, Aricò M, Valsecchi MG, Basso G. Post induction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia. J Clin Oncol. 2014;32:3553-8.

-------------------------------------------------------------------------------------------------------------------

1. D'Angiò M, Valsecchi MG, Testi AM, Conter V, Nunes V, Parasole R, Colombini A, Santoro N, Varotto S, Caniglia M, Silvestri D, Consarino C, Levati L, Magrin E, Locatelli F, Basso G, Foà R, Biondi A, **Cazzaniga G**. Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group. Haematologica. 2015;100:e10-3.
2. Fazio G, Daniele G, Cazzaniga V, Impera L, Severgnini M, Iacobucci I, Galbiati M, Leszl A, Cifola I, De Bellis G, Bresciani P, Martinelli G, Basso G, Biondi A, Storlazzi CT, **Cazzaniga G**. Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2015;100:e14-7.
3. Ceppi F, **Cazzaniga G**, Colombini A, Biondi A, Conter V. Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention. Expert Rev Hematol. 2015 Feb;8(1):57-70. (**Review)**
4. Cazzaniga V, Bugarin C, Bardini M, Giordan M, Te Kronnie G, Basso G, Biondi A, Fazio G, **Cazzaniga G**. LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients. Oncotarget. 2015;6:1569-81.
5. Hasan MN, Queudeville M, Trentin L, Eckhoff SM, Bronzini I, Palmi C, Barth T, **Cazzaniga G**, te Kronnie G, Debatin KM, Meyer LH. Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model. Oncotarget. 2015;6:1382-95.
6. Lana T, de Lorenzo P, Bresolin S, Bronzini I, den Boer ML, Cavé H, Froňková E, Stanulla M, Zaliova M, Harrison CJ, de Groot H, Grazia Valsecchi M, Biondi A, Basso G, **Cazzaniga G**, Te Kronnie G. Refinement of IKZF1 status in pediatric philadelphia positive acute lymphoblastic leukemia. Leukemia. 2015 Mar 17. doi: 10.1038/leu.2015.78
7. Garavelli L, Cordeddu V, Errico S, Bertolini P, Street ME, Rosato S, Pollazzon M, Wischmeijer A, Ivanovski I, Daniele P, Bacchini E, Lombardi AA, Izzi G, Biasucci G, Del Rossi C, Corradi D, **Cazzaniga G**, Dominici C, Rossi C, De Luca A, Bernasconi S, Riccardi R, Legius E, Tartaglia M. Noonan syndrome-like disorder with loose anagen hair: A second case with neuroblastoma. Am J Med Genet A. 2015;167:1902-7.
8. Bugarin C, Sarno J, Palmi C, Savino AM, te Kronnie G, Dworzak M, Shumich A, Buldini B, Maglia O, Sala S, Bronzini I, Bourquin JP, Mejstrikova E, Hrusak O, Luria D, Basso G, Izraeli S, Biondi A, **Cazzaniga G**, Gaipa G; I-BFM study group. Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica. 2015;100:e229-32.
9. Malinowska-Ozdowy K, Frech C, Schönegger A, Eckert C, **Cazzaniga G**, Stanulla M, Zur Stadt U, Mecklenbräuker A, Schuster M, Kneidinger D, von Stackelberg A, Locatelli F, Schrappe M, Horstmann MA, Attarbaschi A, Bock C, Mann G, Haas OA, Panzer-Grümayer R. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. Leukemia. 2015;29:1656-67.
10. Parma M, Viganò C, Fumagalli M, Colnaghi F, Colombo A, Mottadelli F, Rossi V, Elli E, Terruzzi E, Belotti A, **Cazzaniga G**, Pogliani EM, Pioltelli P. Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission. Mediterr J Hematol Infect Dis. 2015;7:e2015041.

-------------------------------------------------------------------------------------------------------------------

1. Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, **Cazzaniga G**, Conter V, Zimmermann M, Moorman AV, Pieters R, den Boer ML. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia. 2016;30:32-8.
2. Fazio G, Gaston-Massuet C, Bettini LR, Graziola F, Scagliotti V, Cereda A, Ferrari L, Mazzola M, **Cazzaniga G**, Giordano A, Cotelli F, Bellipanni G, Biondi A, Selicorni A, Pistocchi A, Massa V. CyclinD1 Down Regulation and Increased Apoptosis Are Common Features of Cohesinopathies. J Cell Physiol. 2016;231:613-22.
3. Pagni F, L'Imperio V, **Cazzaniga G**, Corral L, Doni E, Isimbaldi G. Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma. Expert Rev Hematol. 2015;8:563-5.
4. van der Linden MH, Boer JM, Schneider P, Willekes M, Seslija L, De Lorenzo P, Valsecchi MG, **Cazzaniga G**, Biondi A, den Boer ML, Pieters R, Stam RW. Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities. Haematologica. 2016;101:e95-9.
5. Motta S, Sala D, Sala A, **Cazzaniga G**, Giudici G, Villa N, Biondi A, Selicorni A. Hodgkin lymphoma in a patient with mosaic trisomy 18: First clinical observation. Am J Med Genet A. 2016;170:777-80.
6. Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, Rizzari C, Putti MC, Barisone E, Nigro LL, Santoro N, Ziino O, Pession A, Testi AM, Micalizzi C, Casale F, Pierani P, Cesaro S, Cellini M, Silvestri D, **Cazzaniga G**, Biondi A, Basso G. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematol. 2016;3:e80-6.
7. Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, Locatelli F, **Cazzaniga G**, Niggli F, Aricò M, Bartram CR, Attarbaschi A, Silvestri D, Beier R, Basso G, Ratei R, Kulozik AE, Lo Nigro L, Kremens B, Greiner J, Parasole R, Harbott J, Caruso R, von Stackelberg A, Barisone E, Rössig C, Conter V, Schrappe M. Dexamethasone vs. prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127:2101-12.
8. Jost TR, Borga C, Radaelli E, Romagnani A, Perruzza L, Omodho L, **Cazzaniga G**, Biondi A, Indraccolo S, Thelen M, Te Kronnie G, Grassi F. Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T-cell acute lymphoblastic leukemia. J Leukoc Biol. 2016;99:1077-87.
9. Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, **Cazzaniga G**, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med. 2016;22:379-87.
10. Paganin M, Buldini B, Germano G, Seganfreddo E, Meglio Ad, Magrin E, Grillo F, Pigazzi M, Rizzari C, **Cazzaniga G**, Khiabanian H, Palomero T, Rabadan R, Ferrando AA, Basso G. A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia. Pediatr Blood Cancer. 2016;63:1660-3.
11. Zaliova M, Moorman AV, **Cazzaniga G**, Stanulla M, Harvey RC, Roberts KG, Heatley SL, Loh ML, Konopleva M, Chen IM, Zimmermannova O, Schwab C, Smith O, Mozziconacci MJ, Chabannon C, Kim M, Frederik Falkenburg JH, Norton A, Marshall K, Haas OA, Starkova J, Stuchly J, Hunger SP, White D, Mullighan CG, Willman CL, Stary J, Trka J, Zuna J. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica. 2016;101:1082-93.
12. Palmi C, Savino AM, Silvestri D, Bronzini I, Cario G, Paganin M, Buldini B, Galbiati M, Muckenthaler MU, Bugarin C, Mina PD, Nagel S, Barisone E, Casale F, Locatelli F, Nigro LL, Micalizzi C, Parasole R, Pession A, Putti MC, Santoro N, Testi AM, Ziino O, Kulozik AE, Zimmermann M, Schrappe M, Villa A, Gaipa G, Basso G, Biondi A, Valsecchi MG, Stanulla M, Conter V, Kronnie GT, **Cazzaniga G**. CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget. 2016;7:59260-72.
13. Muñoz-López A, Romero-Moya D, Prieto C, Ramos-Mejía V, Agraz-Doblas A, Varela I, Buschbeck M, Palau A, Carvajal-Vergara X, Giorgetti A, Ford A, Lako M, Granada I, Ruiz-Xivillé N, Rodríguez-Perales S, Torres-Ruíz R, Stam RW, Fuster JL, Fraga MF, Nakanishi M, **Cazzaniga G**, Bardini M, Cobo I, Bayon GF, Fernandez AF, Bueno C, Menendez P. Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. Stem Cell Reports. 2016;7:602-618.
14. Trentin L, Bresolin S, Giarin E, Bardini M, Serafin V, Accordi B, Fais F, Tenca C, De Lorenzo P, Valsecchi MG, **Cazzaniga G**, Te Kronnie G, Basso G. Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis. Sci Rep. 2016;6:34449.
15. Decimi V, Fazio G, Dell'Acqua F, Maitz S, Galbiati M, Rizzari C, Biondi A, **Cazzaniga G\***, Selicorni A. Williams syndrome and mature B-Leukemia: A random association? Eur J Med Genet. 2016;59:634-640 **\*(co-last author)**
16. Scrideli CA, **Cazzaniga G**, Biondi A. Acute Lymphoblastic Leukemia. In: Leonard, DGB (ed). Molecular Biology in Clinical Practice, p337-348, Springer, 2007. (**book chapter**)

-------------------------------------------------------------------------------------------------------------------

1. Manara E, Basso G, Zampini M, Buldini B, Tregnago C, Rondelli R, Masetti R, Bisio V, Frison M, Polato K, **Cazzaniga G**, Menna G, Fagioli F, Merli P, Biondi A, Pession A, Locatelli F, Pigazzi M. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Leukemia. 2017;31:18-25.
2. Cianci P, Fazio G, Casagranda S, Spinelli M, Rizzari C, **Cazzaniga G**, Selicorni A. Acute myeloid leukemia in Baraitser-Winter cerebrofrontofacial syndrome. Am J Med Genet A. 2017 Feb;173(2):546-549
3. Serafin V, Lissandron V, Buldini B, Bresolin S, Paganin M, Grillo F, Andriano N, Palmi C, **Cazzaniga G**, Marmiroli S, Conter V, Basso G, Accordi B. Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL. Leukemia. 2017;31:1007-1011
4. Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, **Cazzaniga G**, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017;542:479-483. Erratum: DOI: 10.1038/s41586-018-0164-5.
5. Savino AM, Sarno J, Trentin L, Vieri M, Fazio G, Bardini M, Bugarin C, Fossati G, Davis K, Gaipa G, Izraeli S, Meyer LH, Nolan GP, Biondi A, Te Kronnie G, Palmi C, **Cazzaniga G**. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. Leukemia. 2017 Mar 23. doi: 10.1038/leu.2017.93. [Epub ahead of print]
6. Vendramini E, Giordan M, Giarin E, Michielotto B, Fazio G, **Cazzaniga G**, Biondi A, Silvestri D, Valsecchi MG, Muckenthaler MU, Kulozik AE, Gattei V, Izraeli S, Basso G, Te Kronnie G. High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. Oncotarget. 2017;8:42398-42413.
7. Langerak AW, Brüggemann M, Davi F, Darzentas N, van Dongen JJM, Gonzalez D, **Cazzaniga G**, Giudicelli V, Lefranc MP, Giraud M, Macintyre EA, Hummel M, Pott C, Groenen PJTA, Stamatopoulos K; EuroClonality-NGS Consortium. High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. J Immunol. 2017 May 15;198(10):3765-3774.
8. **Cazzaniga G**, Bisanti L, Randi G, Deandrea S, Bungaro S, Pregliasco F, Perotti D, Spreafico F, Masera G, Valsecchi MG, Biondi A, Greaves M. Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster. Leukemia. 2017 Aug;31(8):1819-1821.
9. Schwartzman O, Savino AM, Gombert M, Palmi C, Cario G, Schrappe M, Eckert C, von Stackelberg A, Huang JY, Hameiri-Grossman M, Avigad S, Te Kronnie G, Geron I, Birger Y, Rein A, Zarfati G, Fischer U, Mukamel Z, Stanulla M, Biondi A, **Cazzaniga G**, Vetere A, Wagner BK, Chen Z, Chen SJ, Tanay A, Borkhardt A, Izraeli S. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proc Natl Acad Sci U S A. 2017 May 16;114:E4030-E4039
10. Fazio G, Turazzi N, Cazzaniga V, Kreuzaler M, Maglia O, Magnani CF, Biagi E, Rolink A, Biondi A, **Cazzaniga G**. TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia. Br J Haematol. 2017 Jun 1. doi: 10.1111/bjh.14794. [Epub ahead of print]
11. Fazio G, Bettini LR, Rigamonti S, Meta D, Biondi A, **Cazzaniga G**, Selicorni A, Massa V. Impairment of Retinoic Acid Signaling in Cornelia de Lange Syndrome Fibroblasts. Birth Defects Res. 2017 Oct 2;109(16):1268-1276.
12. Turazzi N, Fazio G, Rossi V, Rolink A, **Cazzaniga G**, Biondi A, Magnani CF, Biagi E. Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia. Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14899. [Epub ahead of print]
13. Schwab C, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, Žaliová M, Sutton R, Öfverholm II, Ohki K, Yamashita Y, Groeneveld-Krentz S, Froňková E, Bakkus M, Tchinda J, Barbosa TDC, Fazio G, Mlynarski W, Pastorczak A, **Cazzaniga G**, Pombo-de-Oliveira MS, Trka J, Kirschner-Schwabe R, Imamura T, Barbany G, Stanulla M, Attarbaschi A, Panzer-Grümayer R, Kuiper RP, den Boer ML, Cavé H, Moorman AV, Harrison CJ, Strehl S on behalf of the International Berlin-Frankfurt-Münster (I-BFM) Study Group. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia? Blood Adv. 2017;1:1473-1477.
14. Nunes V, **Cazzaniga G**, Biondi A. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia. Expert Rev Mol Diagn. 2017;17:953-963.**(Review)**

----------------------------------------------------------------------------------------------------------

1. Ceppi F, Gagné V, Douyon L, Quintin CJ, Colombini A, Parasole R, Buldini B, Basso G, Conter V, **Cazzaniga G**, Krajinovic M. DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol. Pharmacogenomics. 2018;19:105-112.
2. **Cazzaniga G**, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, Biondi A. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica. 2018;103:107-115.
3. Bettini LR, Graziola F, Fazio G, Grazioli P, Scagliotti V, Pasquini M, **Cazzaniga G**, Biondi A, Larizza L, Selicorni A, Gaston-Massuet C, Massa V. Rings and Bricks: Expression of Cohesin Components is Dynamic during Development and Adult Life. Int J Mol Sci. 2018;19. pii: E438. doi: 10.3390/ijms19020438.
4. Lovisa F, Zecca M, Rossi B, Campeggio M, Magrin E, Giarin E, Buldini B, Songia S, **Cazzaniga G**, Mina T, Acquafredda G, Quarello P, Locatelli F, Fagioli F, Basso G. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br J Haematol. 2018;180:680-693.
5. Bortolozzi R, Bresolin S, Rampazzo E, Paganin M, Maule F, Mariotto E, Boso D, Minuzzo S, Agnusdei V, Viola G, Te Kronnie G, **Cazzaniga G**, Basso G, Persano L. AKR1C enzymes sustain therapy resistance in paediatric T-ALL. Br J Cancer. 2018;118:985-994.
6. Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, **Cazzaniga G**, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M; TRANSCALL Consortium; International BFM Study Group. IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol. 2018;36:1240-1249
7. Sarno J, Savino AM, Buracchi C, Palmi C, Pinto S, Bugarin C, Jager A, Bresolin S, Barber RC, Silvestri D, Israeli S, Dyer MJS, **Cazzaniga G**, Nolan GP, Biondi A, Davis KL, Gaipa G. SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia. Oncotarget. 2018;9:22872-22885
8. Magnani CF, Mezzanotte C, Cappuzzello C, Bardini M, Tettamanti S, Fazio G, Cooper LJ, Dastoli G, **Cazzaniga G**, Biondi A, Biagi E. Preclinical efficacy and safety of CD19CAR Cytokine-induced killer (CIK) cells transfected with Sleeping Beauty transposon for the treatment of acute lymphoblastic leukemia. Hum Gene Ther. 2018;29:602-613
9. Bardini M, Trentin L, Rizzo F, Vieri M, Savino AM, Garrido Castro P, Fazio G, Van Roon EHJ, Kerstjens M, Smithers N, Prinjha RK, Te Kronnie G, Basso G, Stam RW, Pieters R, Biondi A and **Cazzaniga G**. Anti-leukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4+ infant ALL. Mol Cancer Ther. 2018;17:1705-1716
10. Paganin M, Grillo MF, Silvestri D, Scapinello G, Buldini B, **Cazzaniga G**, Biondi A, Valsecchi MG, Conter V, Te Kronnie G, Basso G. The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols. Br J Haematol. 2018;182:705-711.
11. Stavropoulou V, Almosailleakh M, Royo H, Spetz JF, Juge S, Brault L, Kopp P, Iacovino M, Kyba M, Tzankov A, Stadler MB, **Cazzaniga G**, Peters AHFM, Schwaller J. A Novel Inducible Mouse Model of MLL-ENL-driven Mixed-lineage Acute Leukemia.Hemasphere. 2018;2:e51.
12. Abaji R, Ceppi F, Patel S, Gagné V, Xu CJ, Spinella JF, Colombini A, Parasole R, Buldini B, Basso G, Conter V, **Cazzaniga G**, Leclerc JM, Laverdière C, Sinnett D, Krajinovic M. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics. 2018;19:1181-1193
13. Biondi A, Gandemer V, De Lorenzo P, Cario G, Campbell M, Castor A, Pieters R, Baruchel A, Vora A, Leoni V, Stary J, Escherich G, Li CK, **Cazzaniga G**, Cavé H, Bradtke J, Conter V, Saha V, Schrappe M, Grazia Valsecchi M. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial.Lancet Haematol. 2018;5:e641-e652
14. Galimberti S, Devidas M, Lucenti A, **Cazzaniga G**, Möricke A, Bartram CR, Mann G, Carroll W, Winick N, Borowitz M, Wood B, Basso G, Conter V, Zimmermann M, Suciu S, Biondi A, Schrappe M, Hunger SP, Valsecchi MG. Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia.JNCI Cancer Spectr. 2018;2:pky069.
15. Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, **Cazzaniga G**, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32:273-284.

----------------------------------------------------------------------------------------------------------

1. Bottai D, Spreafico M, Pistocchi A, Fazio G, Adami R, Grazioli P, Canu A, Bragato C, Rigamonti S, Parodi C, **Cazzaniga G**, Biondi A, Cotelli F, Selicorni A, Massa V. Modeling Cornelia de Lange Syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation. Hum Mol Genet. 2019;28:64-73
2. Valli R, Minelli A, Galbiati M, D'Amico G, Frattini A, Montalbano G, Khan AW, Porta G, Millefanti G, Olivieri C, Cipolli M, Cesaro S, Pasquali F, Danesino C, **Cazzaniga G**, Maserati E. Shwachman-Diamond syndrome with clonal interstitial deletion of the long arm of chromosome 20 in bone marrow: haematological features, prognosis and genomic instability. Br J Haematol. 2019;184:974-981
3. Mazzola M, Deflorian G, Pezzotta A, Ferrari L, Fazio G, Bresciani E, Saitta C, Ferrari L, Fumagalli M, Parma M, Marasca F, Bodega B, Riva P, Cotelli F, Biondi A, Marozzi A, **Cazzaniga G**, Pistocchi A. NIPBL: a new player in myeloid cells differentiation. Haematologica. 2019;104:1332-1341
4. Agraz-Doblas A, Bueno C, Bashford-Rogers R, Roy A, Schneider P, Bardini M, Ballerini P, **Cazzaniga G**, Moreno T, Revilla C, Gut M, Valsecchi MG, Roberts I, Pieters R, De Lorenzo P, Varela I, Menendez P, Stam RW. Unravelling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis.Haematologica. 2019;104:1176-1188
5. Portale F, Beneforti L, Fallati A, Biondi A, Palmi C, **Cazzaniga G**, Dander E, D'Amico G. Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia. Exp Hematol. 2019;73:7-12.e4
6. Pfeifer H, **Cazzaniga G**, van der Velden VHJ, Cayuela JM, Schäfer B, Spinelli O, Akiki S, Avigad S, Bendit I, Borg K, Cavé H, Elia L, Reshmi SC, Gerrard G, Hayette S, Hermanson M, Juh A, Jurcek T, Chillón MC, Homburg C, Martinelli G, Kairisto V, Lange T, Lion T, Mueller MC, Pane F, Rai L, Damm-Welk C, Sacha T, Schnittger S, Touloumenidou T, Valerhaugen H, Vandenberghe P, Zuna J, Serve H, Herrmann E, Markovic S, Dongen JJMV, Ottmann OG. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. 2019;33:1910-1922
7. Lopes BA, Meyer C, Barbosa TC, Poubel CP, Mansur MB, Duployez N, Bashton M, Harrison CJ, Zur Stadt U, Horstmann M, Pombo-de-Oliveira MS, Palmi C, **Cazzaniga G**, Venn NC, Sutton R, Alonso CN, Tsaur G, Gupta SK, Bakhshi S, Marschalek R, Emerenciano M. IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia.Transl Oncol. 2019;12:726-732.
8. Meyer C, Lopes BA, Caye-Eude A, Cavé H, Arfeuille C, Cuccuini W, Sutton R, Venn NC, Oh SH, Tsaur G, Escherich G, Feuchtinger T, Kosasih HJ, Khaw SL, Ekert PG, Pombo-de-Oliveira MS, Bidet A, Djahanschiri B, Ebersberger I, Zaliova M, Zuna J, Zermanova Z, Juvonen V, Grümayer RP, Fazio G, **Cazzaniga G**, Larghero P, Emerenciano M, Marschalek R. Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions.Leukemia. 2019;33:2306-2340
9. Fazio G, Massa V, Grioni A, Bystry V, Rigamonti S, Saitta C, Galbiati M, Rizzari C, Consarino C, Biondi A, Selicorni A, **Cazzaniga G**. First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia.J Clin Pathol. 2019;72:558-561
10. Luong-Gardiol N, Siddiqui I, Pizzitola I, Jeevan-Raj B, Charmoy M, Huang Y, Irmisch A, Curtet S, Angelov GS, Danilo M, Juilland M, Bornhauser B, Thome M, Hantschel O, Chalandon Y, **Cazzaniga G**, Bourquin JP, Huelsken J, Held W. γ-Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2019;35:649-663.
11. Federico C, Owoka T, Ragusa D, Sturiale V, Caponnetto D, Leotta CG, Bruno F, Foster HA, Rigamonti S, Giudici G, **Cazzaniga G**, Bridger JM, Sisu C, Saccone S, Tosi S. Deletions of Chromosome 7q Affect Nuclear Organization and HLXB9Gene Expression in Hematological Disorders. Cancers (Basel). 2019;11:585.
12. Knecht H, Reigl T, Kotrová M, Appelt F, Stewart P, Bystry V, Krejci A, Grioni A, Pal K, Stranska K, Plevova K, Rijntjes J, Songia S, Svatoň M, Froňková E, Bartram J, Scheijen B, Herrmann D, García-Sanz R, Hancock J, Moppett J, van Dongen JJM, **Cazzaniga G**, Davi F, Groenen PJTA, Hummel M, Macintyre EA, Stamatopoulos K, Trka J, Langerak AW, Gonzalez D, Pott C, Brüggemann M, Darzentas N; EuroClonality-NGS Working Group. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia. 2019;33:2254-2265
13. Brüggemann M, Kotrová M, Knecht H, Bartram J, Boudjogrha M, Bystry V, Fazio G, Froňková E, Giraud M, Grioni A, Hancock J, Herrmann D, Jiménez C, Krejci A, Moppett J, Reigl T, Salson M, Scheijen B, Schwarz M, Songia S, Svaton M, van Dongen JJM, Villarese P, Wakeman S, Wright G, **Cazzaniga G**, Davi F, García-Sanz R, Gonzalez D, Groenen PJTA, Hummel M, Macintyre EA, Stamatopoulos K, Pott C, Trka J, Darzentas N, Langerak AW; EuroClonality-NGS working group. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.Leukemia. 2019;33:2241-2253
14. Bader P, Salzmann-Manrique E, Balduzzi A, Dalle JH, Woolfrey AE, Bar M, Verneris MR, Borowitz MJ, Shah NN, Gossai N, Shaw PJ, Chen AR, Schultz KR, Kreyenberg H, Di Maio L, **Cazzaniga G**, Eckert C, van der Velden VHJ, Sutton R, Lankester A, Peters C, Klingebiel TE, Willasch AM, Grupp SA, Pulsipher MA. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.Blood Adv. 2019;3:3393-3405.
15. Grioni A, Fazio G, Rigamonti S, Bystry V, Daniele G, Dostalova Z, Quadri M, Saitta C, Silvestri D, Songia S, Storlazzi CT, Biondi A, Darzentas N, **Cazzaniga G**. A Simple RNA Target Capture NGS Strategy for Fusion Genes Assessment in the Diagnostics of Pediatric B-cell Acute Lymphoblastic Leukemia.Hemasphere. 2019;3:e250.

---------------------------------------------------------------------------------------------------

1. Fazio F, Barberi W, **Cazzaniga G**, Fazio G, Messina M, Della Starza I, De Propris MS, Mancini F, Mohamed S, Del Giudice I, Chiaretti S, Moleti ML, Guarini A, Foà R, Testi AM. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript.Leuk Lymphoma. 2020;61:469-472
2. Germano G, Valsecchi MG, Buldini B, **Cazzaniga G**, Zanon C, Silvestri D, Te Kronnie G, Basso G, Paganin M. Next-generation sequencing of PTEN mutations for monitoring minimal residual disease in T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67:e28025.
3. Cario G, Leoni V, Conter V, Attarbaschi A, Zaliova M, Sramkova L, **Cazzaniga G**, Fazio G, Sutton R, Elitzur S, Izraeli S, Lauten M, Locatelli F, Basso G, Buldini B, Bergmann AK, Lentes J, Steinemann D, Göhring G, Schlegelberger B, Haas OA, Schewe D, Buchmann S, Moericke A, White D, Revesz T, Stanulla M, Mann G, Bodmer N, Arad-Cohen N, Zuna J, Valsecchi MG, Zimmermann M, Schrappe M, Biondi A. Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols.Haematologica. 2020;105:1887-1894.
4. Attarbaschi A, Mann G, Zimmermann M, Bader P, Barisone E, Basso G, Biondi A, Cario G, **Cazzaniga G**, Colombini A, Flotho C, Kuhlen M, Lang P, Lauten M, Linderkamp C, Locatelli F, Lo Nigro L, Möricke A, Niggli F, Panzer-Grümayer R, Parasole R, Peters C, Caterina Putti M, Rizzari C, Suttorp M, Valsecchi MG, Conter V, Schrappe M; on behalf of the AIEOP-BFM (Associazione Italiana di Ematologia e Oncologia Pediatrica & Berlin-Frankfurt-Münster) Study Group. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.Leukemia. 2020;34:1694-1700.
5. Schieck M, Lentes J, Thomay K, Hofmann W, Behrens YL, Hagedorn M, Ebersold J, Davenport CF, Fazio G, Möricke A, Buchmann S, Alten J, Cario G, Schrappe M, Bergmann AK, Stanulla M, Steinemann D, Schlegelberger B, Cazzaniga G, Göhring G. Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia. Ann Hematol. 2020;99:809-818.
6. Beneforti L, Dander E, Bresolin S, Bueno C, Acunzo D, Bertagna M, Ford A, Gentner B, te Kronnie G, Vergani P, Menéndez P, Biondi A, D’Amico G, Palmi C and **Cazzaniga G**. Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche. Br J Haematol. 2020;190:262-273
7. Mazzola M, Pezzotta A, Fazio G, Rigamonti A, Bresciani E, Gaudenzi G, Pelleri MC, Saitta C, Ferrari L, Parma M, Fumagalli M, Biondi A, **Cazzaniga G**, Marozzi A, Pistocchi A. Dysregulation of NIPBL leads to impaired RUNX1 expression and haematopoietic defects. J Cell Mol Med. 2020;24:6272-6282.
8. Saettini F, Fazio G, Corti P, Quadri M, Bugarin C, Gaipa G, Penco F, Moratto D, Chiarini M, Baronio M, Gazzurelli L, Imberti L, Paghera S, Giliani S, **Cazzaniga G**, Plebani A, Badolato R, Lougaris V, Gattorno M, Biondi A. Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations. Clin Immunol. 2020;218:108525.
9. Saettini F, Castelli I, Provenzi M, Fazio G, Quadri M, **Cazzaniga G**, Sala S, Dell'Acqua F, Sieni E, Coniglio ML, Pezzoli L, Iascone M, Vendemini F, Balduzzi AC, Biondi A, Rizzari C, Bonanomi S. A novel homozygous disruptive PRF1 variant (K285Sfs\*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2. Pediatr Hematol Oncol. 2020;22:1-5
10. Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borleri G, Fazio G, Zaninelli S, Tettamanti S, Cesana S, Colombo V, Quaroni M, **Cazzaniga G**, Rovelli A, Biagi E, Galimberti S, Calabria A, Benedicenti F, Montini E, Ferrari S, Introna M, Balduzzi A, Valsecchi MG, Dastoli G, Rambaldi A, Biondi A. Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. J Clin Invest. 2020;130:6021-6033.
11. Isidro-Hernández M, Mayado A, Casado-García A, Martínez-Cano J, Palmi C, Fazio G, Orfao A, Ribera J, Ribera JM, Zamora L, Raboso-Gallego J, Blanco O, Alonso-López D, De Las Rivas J, Jiménez R, García Criado FJ, García Cenador MB, Ramírez-Orellana M, **Cazzaniga G**, Cobaleda C, Vicente-Dueñas C, Sánchez-García I. Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis.Sci Rep. 2020;10:19189.
12. Nucera S, Fazio G, Piazza R, Rigamonti S, Fontana D, Gambacorti Passerini C, Maitz S, Rovelli A, Biondi A, **Cazzaniga G**,\* Balduzzi A.\* Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition.Hemasphere. 2020;4:e460. **\*(co-last authors)**
13. D'Angiò M, Fazio G, Grioni A, Palamini S, Sala S, Galbiati M, Biondi A, Balduzzi A, Rizzari C, **Cazzaniga G**. High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case. Hemasphere. 2020;4:e471.

---------------------------------------------------------------------------------------------------

1. **Cazzaniga G**, Songia S, Biondi A; EuroMRD Working Group. PCR Technology to Identify Minimal Residual Disease.Methods Mol Biol. 2021;2185:77-94.
2. Schwab CJ, Roberts KG, Boer JM, Gohring G, Steinemann D, Vora A, Macartney C, Hough RE, Thorn Z, Dillon R, Escherich G, **Cazzaniga G**, Schlegelberger B, Loh ML, Den Boer ML, Moorman AV, Harrison CJ. SSBP2-CSF1R is a Recurrent Fusion in B-lineage Acute Lymphoblastic Leukaemia with Diverse Genetic Presentation and Variable Outcome. Blood. 2021;137:1835-1838.
3. de Barrios O, Galaras A, Trincado JL, Azagra A, Collazo O, Meler A, Agraz-Doblas A, Bueno C, Ballerini P, **Cazzaniga G**, Stam RW, Varela I, De Lorenzo P, Valsecchi MG, Hatzis P, Menéndez P, Parra M. HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia. Leukemia. 2021;35:2086-2091.
4. den Boer ML, Cario G, Moorman AV, Boer JM, de Groot-Kruseman HA, Fiocco M, Escherich G, Imamura T, Yeoh A, Sutton R, Dalla-Pozza L, Kiyokawa N, Schrappe M, Roberts KG, Mullighan CG, Hunger SP, Vora A, Attarbaschi A, Zaliova M, Elitzur S, **Cazzaniga G**, Biondi A, Loh ML, Pieters R; Ponte di Legno Childhood ALL Working Group. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematol. 2021;8:e55-e66.
5. Stutterheim J, van der Sluis IM, de Lorenzo P, Alten J, Ancliffe P, Attarbaschi A, Brethon B, Biondi A, Campbell M, **Cazzaniga G**, Escherich G, Ferster A, Kotecha RS, Lausen B, Li CK, Lo Nigro L, Locatelli F, Marschalek R, Meyer C, Schrappe M, Stary J, Vora A, Zuna J, van der Velden VHJ, Szczepanski T, Valsecchi MG, Pieters R. Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. J Clin Oncol. 2021;39:652-662
6. Saettini F, L'Imperio V, Fazio G, **Cazzaniga G**, Mazza C, Moroni I, Badolato R, Biondi A, Corti P. More than an 'atypical' phenotype: dual molecular diagnosis of autoimmune lymphoproliferative syndrome and Becker muscular dystrophy.Br J Haematol. 2020;191:291-294.
7. Cazzola A, **Cazzaniga G**, Biondi A, Meneveri R, Brunelli S, Azzoni E. Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development. Front Cell Dev Biol. 2021;8:618164. **(review)**
8. Saettini F, Poli C, Vengoechea J, Bonanomi S, Orellana JC, Fazio G, Rodriguez FH, Noguera LP, Booth C, Jarur-Chamy V, Shams M, Iascone M, Vukic M, Gasperini S, Quadri M, Barroeta Seijas A, Rivers E, Mauri M, Badolato R, **Cazzaniga G**, Bugarin C, Gaipa G, Kroes WGM, Moratto D, van Oostaijen-Ten Dam MM, Baas F, van der Maarel S, Piazza R, Coban-Akdemir ZH, Lupski JR, Yuan B, Chinn IK, Daxinger L, Biondi A. Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency. Blood. 2021;137:493-499
9. van der Velden VHJ, Brüggemann M, **Cazzaniga G**, Scheijen B, Tops B, Trka J, Pal K, Hänzelmann S, Fazio G, Songia S, Langerak AW, Darzentas N; EuroMRD; EuroClonality-NGS Working Group. Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study. Leukemia. 2021;35:924-928.
10. Della Starza I, Nunes V, Lovisa F, Silvestri D, Cavalli M, Garofalo A, Campeggio M, De Novi LA, Soscia R, Oggioni C, Mussolin L, Biondi A, Guarini A, Valsecchi MG, Conter V, Biffi A, Basso G, Foà R, **Cazzaniga G**. Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. Hemasphere. 2021;5:e543
11. Hirabayashi S, Butler ER, Ohki K, Kiyokawa N, Bergmann AK, Möricke A, Boer JM, Cavé H, **Cazzaniga G**, Yeoh AEJ, Sanada M, Imamura T, Inaba H, Mullighan C, Loh ML, Norén-Nyström U, Pastorczak A, Shih LY, Zaliova M, Pui CH, Haas OA, Harrison CJ, Moorman AV, Manabe A. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia. 2021;35:3272-3277.
12. Fazio G, Bardini M, De Lorenzo P, Grioni A, Quadri M, Pedace L, Corral L, Palamini S, Palmi C, Buldini B, Vinti L, Parasole R, Barisone E, Zecca M, Favre C, Locatelli F, Conter V, Rizzari C, Valsecchi MG, Biondi A, and **Cazzaniga G**. Recurrent genetic fusions redefine MLL-germline acute lymphoblastic leukemia in Infants. Blood. 2021;137:1980-1984
13. Saettini F, Fazio G, Moratto D, Galbiati M, Zucchini N, Ippolito D, Dinelli ME, Imberti L, Mauri M, Melzi ML, Bonanomi S, Gerussi A, Pinelli M, Barisani C, Bugarin C, Chiarini M, Giacomelli M, Piazza R, **Cazzaniga G**, Invernizzi P, Giliani SC, Badolato R, Biondi A. Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis.Front Immunol. 2021 Apr 16;12:673487
14. Dander E., Palmi C., D'Amico G and **Cazzaniga G**. The bone marrow niche in B-cell acute lymphoblastic leukemia: the role of microenvironment from pre-leukemia to overt leukemia. Int J Mol Sci. 2021;22:4426. (**review**)
15. Tejedor JR, Bueno C, Vinyoles M, Petazzi P, Agraz-Doblas A, Cobo I, Torres-Ruiz R, Bayón GF, Pérez RF, López-Tamargo S, Gutierrez-Agüera F, Santamarina-Ojeda P, Ramírez-Orellana M, Bardini M, **Cazzaniga G**, Ballerini P, Schneider P, Stam RW, Varela I, Fraga MF, Fernández AF, Menéndez P. Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B-cell acute lymphoblastic leukemia. J Clin Invest. 2021;131:e138833
16. Quintarelli C, Guercio M, Manni S, Boffa I, Sinibaldi M, Di Cecca S, Caruso S, Abbaszadeh Z, Camera A, Cembrola B, Ciccone R, Orfao A, Martin-Martin L, Gutierrez-Herrero S, Herrero-Garcia M, **Cazzanig**a G, Nunes V, Songia S, Marcatili P, Marin F, Ruella M, Bertaina V, Vinti L, Del Bufalo F, Algeri M, Merli P, De Angelis B, Locatelli F. Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. J Immunother Cancer. 2021;9:e001514.
17. Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz MJ, Campbell M, Cario G, **Cazzaniga G**, Escherich G, Harrison CJ, Heyman M, Hunger SP, Kiss C, Liu H-C, Locatelli F, Loh ML, Manabe A, Mann G, Pieters R, Pui C-H, Rives S, Schmiegelow K, Silverman LB, Stary J, Vora A, Brown PA. Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium. Blood. 2022;139:1785-1793
18. Boer JM, Valsecchi MG, Hormann FM, Antić Z, Zaliova M, Schwab C, **Cazzaniga G**, Arfeuille C, Cavé H, Attarbaschi A, Strehl S, Escherich G, Imamura T, Ohki K, Grüber TA, Sutton R, Pastorczak A, Lammens T, Lambert F, Li CK, Carrillo de Santa Pau E, Hoffmann S, Möricke A, Harrison CJ, Den Boer ML, De Lorenzo P, Stam RW, Bergmann AK, Pieters R. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia. 2021;35:2978-2982
19. Ceppi F, Rizzati F, Colombini A, Conter V, **Cazzaniga** G.Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia.Expert Rev Hematol. 2021;14:795-807. (**review**)
20. Stewart JP, Gazdova J, Darzentas N, Wren D, Proszek P, Fazio G, Songia S, Alcoceba M, Sarasquete ME, Villarese P, van der Klift MY, Heezen KC, McCafferty N, Pal K, Catherwood M, Kim CS, Srivastava S, Kroeze LI, Hodges E, Stamatopoulos K, Klapper W, Genuardi E, Ferrero S, van den Brand M, **Cazzaniga** G, Davi F, Sutton LA, Garcia-Sanz R, Groenen PJTA, Macintyre EA, Brüggemann M, Pott C, Langerak AW, Gonzalez D; EuroClonality-NGS Working Group. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. Blood Adv. 2021;5:3188-3198.
21. Russo A, Viberti C, Mareschi K, Casalone E, Guarrera S, Birolo G, **Cazzaniga** G, Corral L, Trentin L, Basso G, Fagioli F, Matullo G. Genetic and Epigenetic Characterization of a Discordant KMT2A/AFF1-Rearranged Infant Monozygotic Twin Pair. Int J Mol Sci. 2021;22:9740.
22. Turati VA, Guerra-Assunção JA, Potter NE, Gupta R, Ecker S, Daneviciute A, Tarabichi M, Webster AP, Ding C, May G, James C, Brown J, Conde L, Russell LJ, Ancliff P, Inglott S, **Cazzaniga** G, Biondi A, Hall GW, Lynch M, Hubank M, Macaulay I, Beck S, Van Loo P, Jacobsen SE, Greaves M, Herrero J, Enver T. Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia.Nat Cancer. 2021;2:835-852.

---------------------------------------------------------------------------------------------------

1. Antić Ž, Yu J, Bornhauser BC, Lelieveld SH, van der Ham CG, van Reijmersdal SV, Morgado L, Elitzur S, Bourquin JP, **Cazzaniga** G, Eckert C, Camós M, Sutton R, Cavé H, Moorman AV, Sonneveld E, Geurts van Kessel A, van Leeuwen FN, Hoogerbrugge PM, Waanders E, Kuiper RP.Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse. Pediatr Blood Cancer. 2022;69:e29361
2. Stutterheim J, de Lorenzo P, van der Sluin IM, Alten J, Ancliffe P, Attarbaschi A, Aversa L, Boer JM, Biondi A, Brethon B, Diaz P, **Cazzaniga** G, Escherich G, Ferster A, Kotecha RS, Lausen B, Leung AW, Locatelli F, Silverman L, Stary J, Szczepanski T, van der Velden VHJ, Vora A, Zuna J, Schrappe M, Valsecchi MG, Pieters R. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.Eur J Cancer. 2022;160:72-79
3. Saettini F, Fazio G, Bonati MT, Moratto D, Massa V, Di Fede E, Castiglioni S, Marchetti D, Chiarini M, Sottini A, Iascone M, **Cazzaniga G**, Imberti L, Biondi A, Gervasini C, Badolato R. Identical EP300 variant leading to Rubinstein-Taybi syndrome with different clinical and immunologic phenotype. Am J Med Genet A. 2022 Mar 9. doi: 10.1002/ajmg.a.62719. Online ahead of print.
4. Bomken S, Enshaei A, Schwalbe EC, Mikulasova A, Dai Y, Zaka M, Fung KT, Bashton M, Lim H, Jones L, Karataraki N, Winterman E, Ashby C, Attarbaschi A, Bertrand Y, Bradtke J, Buldini B, Burke GA, **Cazzaniga G**, Gohring G, De Groot-Kruseman HA, Haferlach C, Nigro LL, Parihar M, Plesa A, Seaford E, Sonneveld E, Strehl S, Van der Velden VH, Rand V, Hunger SP, Harrison CJ, Bacon CM, Van Delft FW, Loh ML, Moppett J, Vormoor J, Walker BA, Moorman AV, Russell LJ. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2021.280557. Online ahead of print. PMID: 35484682
5. Schedel A, Friedrich UA, Morcos MNF, Wagener R, Mehtonen J, Watrin T, Saitta C, Brozou T, Michler P, Walter C, Försti A, Baksi A, Menzel M, Horak P, Paramasivam N, Fazio G, Autry RJ, Fröhling S, Suttorp M, Gertzen C, Gohlke H, Bhatia S, Wadt K, Schmiegelow K, Dugas M, Richter D, Glimm H, Heinäniemi M, Jessberger R, **Cazzaniga G**, Borkhardt A, Hauer J, Auer F. Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma. Int J Mol Sci. 2022 May 5;23(9):5174. doi: 10.3390/ijms23095174. PMID: 35563565
6. Della Starza I, Eckert C, Drandi D, **Cazzaniga G**; EuroMRD Consortium. Minimal Residual Disease Analysis by Monitoring Immunoglobulin and T-Cell Receptor Gene Rearrangements by Quantitative PCR and Droplet Digital PCR. Methods Mol Biol. 2022;2453:79-89. doi: 10.1007/978-1-0716-2115-8\_5. PMID: 35622321 (**book chapter**)
7. Lo Nigro L, Andriano N, Buldini B, Silvestri D, Villa T, Locatelli F, Parasole R, Barisone E, Testi AM, Biondi A, Valsecchi MG, Rizzari C, Conter V, Basso G, **Cazzaniga G**. FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD). Cancers (Basel). 2022 May 17;14(10):2475. doi: 10.3390/cancers14102475. PMID: 35626079
8. Saitta C, Rebellato S, Bettini LR, Giudici G, Panini N, Erba E, Massa V, Auer F, Friedrich U, Hauer J, Biondi A, Fazio G, **Cazzaniga G**. Potential role of STAG1 mutations in genetic predisposition to childhood hematological malignancies. Blood Cancer J. 2022 Jun 2;12(6):88. doi: 10.1038/s41408-022-00683-9. PMID: 35654786
9. Ramos-Muntada M, Trincado JL, Blanco J, Bueno C, Rodríguez-Cortez VC, Bataller A, López-Millán B, Schwab C, Ortega M, Velasco P, Blanco ML, Nomdedeu J, Ramírez-Orellana M, Minguela A, Fuster JL, Cuatrecasas E, Camós M, Ballerini P, Escherich G, Boer J, denBoer M, Hernández-Rivas JM, Calasanz MJ, **Cazzaniga G**, Harrison CJ, Menéndez P, Molina OClonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia. Mol Oncol. 2022 Jun 21. doi: 10.1002/1878-0261.13276. 1. PMID: 35726693
10. Külp M, Siemund AL, Larghero P, Dietz A, Alten J, Cario G, Eckert C, Caye-Eude A, Cavé H, Bardini M, **Cazzaniga G**, De Lorenzo P, Valsecchi MG, Diehl L, Bonig H, Meyer C, Marschalek R. The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia. iScience. 2022 Jun 16;25(7):104613. doi: 10.1016/j.isci.2022.104613. eCollection 2022 Jul 15. PMID: 35800767
11. Severgnini M, D'Angiò M, Bungaro S, **Cazzaniga G**,\* Cifola I, Fazio G. Conjoined Genes as Common Events in Childhood Acute Lymphoblastic Leukemia. Cancers (Basel). 2022 Jul 20;14(14):3523. doi: 10.3390/cancers14143523. PMID: 35884588 \**corresponding*
12. Pezzotta A, Gentile I, Genovese D, Totaro MG, Battaglia C, Leung AY, Fumagalli M, Parma M, **Cazzaniga G**, Fazio G, Alcalay M, Marozzi A, Pistocchi A. HDAC6 inhibition decreases leukemic stem cell expansion driven by Hedgehog hyperactivation by restoring primary ciliogenesis. Pharmacol Res. 2022 Jul 30:106378. doi: 10.1016/j.phrs.2022.106378. PMID: 35918044
13. Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, Fronkova E, Alten J, Koehler R, Eckert C, Brizzolara L, Trkova M, Stuchly J, Zimmermann M, De Lorenzo P, Valsecchi MG, Conter V, Stary J, Schrappe M, Biondi A, Trka J, Zaliova M,\* **Cazzaniga G**,\* Cario G.\* Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia. 2022 Aug 6. doi: 10.1038/s41375-022-01668-0. Online ahead of print. PMID: 35933523 \**co-last*
14. Saettini F, Coliva TA, Vendemini F, Galbiati M, Bugarin C, Masetti R, Moratto D, Chiarini M, Guerra F, Iascone M, Badolato R, **Cazzaniga G**, Niemeyer C, Flotho C, Biondi A. Abnormal B-Cell Maturation and Increased Transitional B Cells in CBL Syndrome. Front Pediatr. 2022 Jul 28;10:935951. doi: 10.3389/fped.2022.935951. eCollection 2022. PMID: 35967575
15. Fazio G, Bresolin S, Silvestri D, Quadri M, Saitta C, Vendramini E, Buldini B, Palmi C, Bardini M, Grioni A, Rigamonti S, Galbiati M, Mecca S, Savino AM, Peloso A, Tu JW, Bhatia S, Borkhardt A, Micalizzi C, Lo Nigro L, Locatelli F, Conter V, Rizzari C, Valsecchi MG, Te Kronnie G, Biondi A, **Cazzaniga G**. PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120. EBioMedicine. 2022 Aug 16;83:104224. doi: 10.1016/j.ebiom.2022.104224. Online ahead of print. PMID: 35985167
16. Soscia R, Della Starza I, De Novi LA, Ilari C, Ansuinelli M, Cavalli M, Bellomarino V, Cafforio L, Di Trani M, **Cazzaniga** G, Fazio G, Santoro A, Salemi D, Spinelli O, Tosi M, Terragna C, Robustelli V, Bellissimo T, Colafigli G, Breccia M, Chiaretti S, Di Rocco A, Martelli M, Guarini A, Del Giudice I, Foà R. Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases. Hematol Oncol. 2022 Oct 17. doi: 10.1002/hon.3087. Online ahead of print.
17. Ohki K, Butler ER, Kiyokawa N, Hirabayashi S, Bergmann AK, Möricke A, Boer JM, Cavé H, **Cazzaniga** G, Yeoh AEJ, Sanada M, Imamura T, Inaba H, Mullighan CG, Loh ML, Norén-Nyström U, Shih LY, Zaliova M, Pui CH, Haas OA, Harrison CJ, Moorman AV, Manabe A. Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group. Leukemia. 2022 Oct 29. doi: 10.1038/s41375-022-01737-4. Online ahead of print.

----------------------------------------------------------------------------------------------------------

1. Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gröger D, Sutton R, Venn NC, **Cazzaniga G**, Corral Abascal L, Tsaur G, Fechina L, Emerenciano M, Pombo-de-Oliveira MS, Lund-Aho T, Lundán T, Montonen M, Juvonen V, Zuna J, Trka J, Ballerini P, Lapillonne H, Van der Velden VHJ, Sonneveld E, Delabesse E, de Matos RRC, Silva MLM, Bomken S, Katsibardi K, Keernik M, Grardel N, Mason J, Price R, Kim J, Eckert C, Lo Nigro L, Bueno C, Menendez P, Zur Stadt U, Gameiro P, Sedék L, Szczepański T, Bidet A, Marcu V, Shichrur K, Izraeli S, Madsen HO, Schäfer BW, Kubetzko S, Kim R, Clappier E, Trautmann H, Brüggemann M, Archer P, Hancock J, Alten J, Möricke A, Stanulla M, Lentes J, Bergmann AK, Strehl S, Köhrer S, Nebral K, Dworzak MN, Haas OA, Arfeuille C, Caye-Eude A, Cavé H, Marschalek R. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023 May;37(5):988-1005. doi: 10.1038/s41375-023-01877-1. Epub 2023 Apr 5. PMID: 37019990
2. Külp M, Larghero P, Alten J, Cario G, Eckert C, Caye-Eude A, Cavé H, Schmachtel T, Bardini M, **Cazzaniga G**, De Lorenzo P, Valsecchi MG, Bonig H, Meyer C, Rieger MA, Marschalek R. The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome. Leukemia. 2023 Jun;37(6):1216-1233. doi: 10.1038/s41375-023-01895-z. Epub 2023 Apr 26. PMID: 37100882
3. Palmi C, Bresolin S, Junk S, Fazio G, Silvestri D, Zaliova M, Oikonomou A, Scharov K, Stanulla M, Moericke A, Zimmermann M, Schrappe M, Buldini B, Bhatia S, Borkhardt A, Saitta C, Galbiati M, Bardini M, Lo Nigro L, Conter V, Valsecchi MG, Biondi A, Te Kronnie G, Cario G, **Cazzaniga G**. Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia. Hemasphere. 2023 May 26;7(6):e892. doi: 10.1097/HS9.0000000000000892. eCollection 2023 Jun. PMID: 37304931
4. Lopes BA, Meyer C, Bouzada H, Külp M, Maciel ALT, Larghero P, Barbosa TC, Poubel CP, Barbieri C, Venn NC, Pozza LD, Barbaric D, Palmi C, Fazio G, Saitta C, Aguiar TF, Lins MM, Ikoma-Colturato MRV, Schramm M, Chapchap E, **Cazzaniga G**, Sutton R, Marschalek R, Emerenciano M. The recombinome of IKZF1 deletions in B-cell precursor ALL. Leukemia. 2023 Aug;37(8):1727-1731. doi: 10.1038/s41375-023-01935-8. Epub 2023 Jun 29. PMID: 37386080
5. Hunger SP, Tran TH, Saha V, Devidas M, Valsecchi MG, Gastier-Foster JM, **Cazzaniga G**, Reshmi SC, Borowitz MJ, Moorman AV, Heerema NA, Carroll AJ, Martin-Regueira P, Loh ML, Raetz EA, Schultz KR, Slayton WB, Cario G, Schrappe M, Silverman LB, Biondi A. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023 Jul;10(7):e510-e520. doi: 10.1016/S2352-3026(23)00088-1. PMID: 37407142
6. Zuna J, Hovorkova L, Krotka J, Winkowska L, Novak Z, Sramkova L, Stary J, Trka J, **Cazzaniga G**, Cario G, Zaliova M. Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track? Am J Hematol. 2023 Oct;98(10):E269-E271. doi: 10.1002/ajh.27022. Epub 2023 Jul 14. PMID: 37449465
7. Barone C, Orsenigo R, Cazzola A, D'Errico E, Patelli A, Quattrini G, Vergani B, Bombelli S, De Marco S, D'Orlando C, Bianchi C, Leone BE, Meneveri R, Biondi A, **Cazzaniga G**, Rabbitts TH, Brunelli S, Azzoni E. Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation. Cancers (Basel). 2023 Jul 14;15(14):3624. doi: 10.3390/cancers15143624. PMID: 37509285
8. Caserta C, Nucera S, Barcella M, Fazio G, Naldini MM, Pagani R, Pavesi F, Desantis G, Zonari E, D'Angiò M, Capasso P, Lombardo A, Merelli I, Spinelli O, Rambaldi A, Ciceri F, Silvestri D, Valsecchi MG, Biondi A, **Cazzaniga G**, Gentner B. miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease. Leukemia. 2023 Oct;37(10):1994-2005. doi: 10.1038/s41375-023-02009-5. Epub 2023 Aug 28. PMID: 37640845
9. Oikonomou A, Valsecchi L, Quadri M, Watrin T, Scharov K, Procopio S, Tu JW, Vogt M, Savino AM, Silvestri D, Valsecchi MG, Biondi A, Borkhardt A, Bhatia S, **Cazzaniga G**, Fazio G, Bardini M, Palmi C. High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia. Biochem Pharmacol. 2023 Nov;217:115809. doi: 10.1016/j.bcp.2023.115809. Epub 2023 Sep 17. PMID: 37717691
10. Saettini F, Guerra F, Fazio G, Bugarin C, McMillan HJ, Ohtake A, Ardissone A, Itoh M, Giglio S, Cappuccio G, Giardino G, Romano R, Quadri M, Gasperini S, Moratto D, Chiarini M, Akira I, Fukuhara Y, Hayakawa I, Okazaki Y, Mauri M, Piazza R, **Cazzaniga G**, Biondi A. Antibody Deficiency in Patients with Biallelic KARS1 Mutations. J Clin Immunol. 2023;43:2115-2125. Correction in J Clin Immunol. 2023 Nov;43(8):2126
11. Hess JF, Kotrová M, Fricke B, Songia S, Rigamonti S, Cavagna R, Tosi M, Paust N, Langerak AW, Spinelli O, **Cazzaniga G**, Brüggemann M, Hutzenlaub T. Clinical pilot study on microfluidic automation of IGH-VJ library preparation for next generation sequencing. Clin Chem Lab Med. 2023 Dec 29. doi: 10.1515/cclm-2023-1346. Online ahead of print. PMID: 38153095

----------------------------------------------------------------------------------------------------------

1. Crespiatico I, Zaghi M, Mastini C, D'Aliberti D, Mauri M, Mercado CM, Fontana D, Spinelli S, Crippa V, Inzoli E, Manghisi B, Civettini I Medical Doctor, Ramazzotti D, Sangiorgio V, Gengotti M, Brambilla V, Aroldi A, Banfi F, Barone C, Orsenigo R, Riera L, Riminucci M, Corsi A, Breccia M, Morotti A, Cilloni D, Roccaro AM, Sacco A, Stagno F, Serafini M, Mottadelli F, **Cazzaniga** G, Pagni F, Chiarle R, Azzoni E, Sessa A, Gambacorti-Passerini CB, Elli EM, Mologni L, Piazza R. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood. 2024 Jan 9:blood.2023021349. doi: 10.1182/blood.2023021349. Online ahead of print. PMID: 38194688
2. Buldini B, Varotto E, Maurer-Granofszky M, Gaipa G, Schumich A, Brüggemann M, Mejstrikova E, **Cazzaniga** G, Hrusak O, Szczepanowski M, Scarparo P, Zimmermann M, Strehl S, Schinnerl D, Zaliova M, Karawajew L, Bourquin JP, Feuerstein T, Cario G, Alten J, Möricke A, Biffi A, Parasole R, Fagioli F, Valsecchi MG, Biondi A, Locatelli F, Attarbaschi A, Schrappe M, Conter V, Basso G, Dworzak MN. CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment. Blood. 2024 Jan 12:blood.2023021952. doi: 10.1182/blood.2023021952. Online ahead of print. PMID: 38215390
3. Elli EM, Mauri M, D'Aliberti D, Crespiatico I, Fontana D, Redaelli S, Pelucchi S, Spinelli S, Manghisi B, Cavalca F, Aroldi A, Ripamonti A, Ferrari S, Palamini S, Mottadelli F, Massimino L, Ramazzotti D, **Cazzaniga** G, Piperno A, Gambacorti-Passerini C, Piazza R. Idiopathic erythrocytosis: a germline disease? Clin Exp Med. 2024 Jan 20;24(1):11. doi: 10.1007/s10238-023-01283-y. PMID: 38244120 Free PMC article.
4. Conter V, Valsecchi MG, Cario G, Zimmermann M, Attarbaschi A, Stary J, Niggli F, Dalla Pozza L, Elitzur S, Silvestri D, Locatelli F, Möricke A, Engstler G, Smisek P, Bodmer N, Barbaric D, Izraeli S, Rizzari C, Boos J, Buldini B, Zucchetti M, von Stackelberg A, Matteo C, Lehrnbecher T, Lanvers-Kaminsky C, **Cazzaniga** G, Gruhn B, Biondi A, Schrappe M. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. J Clin Oncol. 2024 Mar 10;42(8):915-926. doi: 10.1200/JCO.23.01388. Epub 2023 Dec 14. PMID: 38096462
5. Tretti Parenzan C, Dal Molin A, Longo G, Gaffo E, Buratin A, Cani A, Boldrin E, Serafin V, Guglielmelli P, Vannucchi AM, Cazzaniga G, Biondi A, Locatelli F, Meyer LH, Buldini B, Te Kronnie G, Bresolin S, Bortoluzzi S. Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion. Blood Adv. 2024 Mar 12;8(5):1305-1319. doi: 10.1182/bloodadvances.2023011291. PMID: 38029383